1
|
Dillman JR, Tkach JA, Fletcher JG, Bruining DH, Lu A, Kugathasan S, Alazraki AL, Knight-Scott J, Stidham RW, Adler J, Minar P, Trapnell BC, Bonkowski EL, Jurrell H, Lopez-Nunez O, Collins MH, Swanson SD, Fei L, Qian L, Towbin AJ, Kocaoglu M, Anton CG, Imbus RA, Dudley JA, Denson LA. Circulating and Magnetic Resonance Imaging Biomarkers of Intestinal Fibrosis in Small Bowel Crohn's Disease. Inflamm Bowel Dis 2025:izae319. [PMID: 39853252 DOI: 10.1093/ibd/izae319] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/08/2024] [Indexed: 01/26/2025]
Abstract
BACKGROUND We previously identified circulating and MRI biomarkers associated with the surgical management of Crohn's disease (CD). Here we tested associations between these biomarkers and ileal resection inflammation and collagen content. METHODS Fifty CD patients undergoing ileal resection were prospectively enrolled at 4 centers. Circulating CD64, extracellular matrix protein 1 (ECM1), GM-CSF autoantibodies (GM-CSF Ab), and fecal calprotectin were measured by ELISA. Ileal 3-dimensional magnetization transfer ratio (3D MTR), modified Look-Locker inversion recovery (MOLLI) T1 relaxation, diffusion-weighted intravoxel incoherent motion (IVIM), and the simplified magnetic resonance index of activity (sMaRIA) were measured by MRI. Ileal resection specimen acute inflammation was graded, and collagen content was measured quantitatively using second harmonic imaging microscopy. Associations between biomarkers and ileal collagen content were tested. RESULTS Median (interquartile range [IQR]) age was 19.5 (16-33) years. We observed an inverse relationship between ileal acute inflammation and collagen content (r = -0.39 [95% confidence interval {CI}: -0.61, -0.10], P = .008). Most patients (33 [66%]) received biologics, with no variation in collagen content with treatment exposures. In the univariate analysis, CD64, GM-CSF Ab, fecal calprotectin, and sMaRIA were positively associated with acute inflammation and negatively associated with collagen content (P < .1). The multivariable model for ileal collagen content (R2 = 0.31 [95% CI: 0.11, 0.52]) included log CD64 (β = -.27; P = .19), log ECM1 (β = .47; P = .06), log GM-CSF Ab (β = -.15; P = .01), IVIM f (β = .29, P = .10), and IVIM D* (β = 1.69, P = .13). CONCLUSIONS Clinically available and exploratory circulating and MRI biomarkers are associated with the degree of inflammation versus fibrosis in CD ileal resections. With further validation, these biomarkers may be used to guide medical and surgical decision-making for refractory CD.
Collapse
Affiliation(s)
- Jonathan R Dillman
- Department of Radiology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA
| | - Jean A Tkach
- Department of Radiology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA
| | | | - David H Bruining
- Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA
| | - Aiming Lu
- Department of Radiology, Mayo Clinic, Rochester, MN, USA
| | - Subra Kugathasan
- Department of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA, USA
| | - Adina L Alazraki
- Department of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA, USA
- Department of Radiology, Emory University School of Medicine, Children's Healthcare of Atlanta, Atlanta, GA, USA
| | - Jack Knight-Scott
- Department of Radiology, Emory University School of Medicine, Children's Healthcare of Atlanta, Atlanta, GA, USA
| | - Ryan W Stidham
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, USA
| | - Jeremy Adler
- Division of Pediatric Gastroenterology, Department of Pediatrics, C. S. Mott Children's Hospital, Michigan Medicine, Ann Arbor, MI, USA
| | - Phillip Minar
- Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA
| | - Bruce C Trapnell
- Departments of Medicine and Pediatrics, Translational Pulmonary Science Center, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA
| | - Erin L Bonkowski
- Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA
| | - Holden Jurrell
- Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA
| | - Oscar Lopez-Nunez
- Division of Pathology and Laboratory Medicine, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA
| | - Margaret H Collins
- Division of Pathology and Laboratory Medicine, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA
| | - Scott D Swanson
- Department of Radiology, Michigan Medicine, Ann Arbor, MI, USA
| | - Lin Fei
- Division of Biostatistics and Epidemiology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA
| | - Lucia Qian
- Division of Biostatistics and Epidemiology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA
- University of Michigan, Ann Arbor, MI, USA
| | - Alexander J Towbin
- Department of Radiology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA
| | - Murat Kocaoglu
- Department of Radiology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA
| | - Christopher G Anton
- Department of Radiology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA
| | - Rebecca A Imbus
- Department of Radiology, Imaging Research Center, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
| | - Jonathan A Dudley
- Department of Radiology, Imaging Research Center, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
| | - Lee A Denson
- Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA
| |
Collapse
|
2
|
Dragoni G, Ke BJ, Picariello L, Abdurahiman S, Ceni E, Biscu F, Mello T, Polvani S, Innocenti T, Spalart V, Milani S, D'Hoore A, Bislenghi G, Scaringi S, Verstockt B, De Hertogh G, Martinod K, Galli A, Matteoli G, Vermeire S. The Impact of Peptidyl Arginine Deiminase 4-Dependent Neutrophil Extracellular Trap Formation on the Early Development of Intestinal Fibrosis in Crohn's Disease. J Crohns Colitis 2025; 19:jjae121. [PMID: 39126198 DOI: 10.1093/ecco-jcc/jjae121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/17/2023] [Revised: 06/29/2024] [Accepted: 08/08/2024] [Indexed: 08/12/2024]
Abstract
BACKGROUND AND AIMS During early phases of inflammation, activated neutrophils extrude neutrophil extracellular traps (NETs) in a peptidyl arginine deiminase 4 (PAD4)-dependent manner, aggravating tissue injury and remodeling. In this study, we investigated the potential pro-fibrotic properties and signaling of NETs in Crohn's disease (CD). METHODS NETs and activated fibroblasts were labeled on resected ileum from CD patients by multiplex immunofluorescence staining. NETs-treated human primary intestinal fibroblasts were analyzed by bulk RNA sequencing to uncover cell signaling pathways, and by high-throughput imaging to assess collagen production and migratory activity. Consequentially, TLR2/NF-κB pathway was evaluated by transfection of CCD-18Co fibroblasts with an NF-κB-luciferase reporter plasmid, incorporating C29 to block TLR2 signaling. A chronic dextran sulfate sodium (DSS) mouse model was used to define the specific role of PAD4 deletion in neutrophils (MRP8-Cre, Pad4fl/fl). RESULTS Immunofluorescence showed spatial colocalization of NETs and activated fibroblasts in ileal ulcerations of CD patients. Transcriptomic analysis revealed upregulation of pro-fibrotic genes and activation of Toll-like receptor signaling pathways in NETs-treated fibroblasts. NETs treatment induced fibroblast proliferation, diminished migratory capability, and increased collagen release. Transfection experiments indicated a substantial increase in an NF-κB expression with NETs, whereas C29 led to decreased expression and release of collagen. In line, a significant reduction in collagen content was observed in the colon of MRP8-Cre, Pad4fl/fl mice subjected to chronic DSS colitis. CONCLUSIONS NETs potentially serve as an initial stimulus for pathological activation of fibroblasts within the intestine via the TLR2/NF-κB pathway. Given their early involvement in inflammation, inhibition of PAD4 might offer a strategy to modulate both inflammation and fibrogenesis in CD.
Collapse
Affiliation(s)
- Gabriele Dragoni
- Department of Chronic Diseases and Metabolism, Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven, Leuven, Belgium
- Gastroenterology Research Unit, Department of Experimental and Clinical Biochemical Sciences "Mario Serio", University of Florence, Florence, Italy
- Department of Gastroenterology, IBD Referral Center, Careggi University Hospital, Florence, Italy
| | - Bo-Jun Ke
- Laboratory for Mucosal Immunology, Department of Chronic Diseases, Metabolism and Ageing, Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven, Leuven, Belgium
| | - Lucia Picariello
- Gastroenterology Research Unit, Department of Experimental and Clinical Biochemical Sciences "Mario Serio", University of Florence, Florence, Italy
| | - Saeed Abdurahiman
- Laboratory for Mucosal Immunology, Department of Chronic Diseases, Metabolism and Ageing, Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven, Leuven, Belgium
| | - Elisabetta Ceni
- Gastroenterology Research Unit, Department of Experimental and Clinical Biochemical Sciences "Mario Serio", University of Florence, Florence, Italy
| | - Francesca Biscu
- Laboratory for Mucosal Immunology, Department of Chronic Diseases, Metabolism and Ageing, Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven, Leuven, Belgium
- Centre for Inflammation Research, University of Edinburgh, Edinburgh, UK
| | - Tommaso Mello
- Gastroenterology Research Unit, Department of Experimental and Clinical Biochemical Sciences "Mario Serio", University of Florence, Florence, Italy
| | - Simone Polvani
- Gastroenterology Research Unit, Department of Experimental and Clinical Biochemical Sciences "Mario Serio", University of Florence, Florence, Italy
| | - Tommaso Innocenti
- Department of Chronic Diseases and Metabolism, Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven, Leuven, Belgium
- Gastroenterology Research Unit, Department of Experimental and Clinical Biochemical Sciences "Mario Serio", University of Florence, Florence, Italy
- Department of Gastroenterology, IBD Referral Center, Careggi University Hospital, Florence, Italy
| | - Valérie Spalart
- Department of Cardiovascular Sciences, Center for Molecular and Vascular Biology, KU Leuven, Leuven, Belgium
| | - Stefano Milani
- Gastroenterology Research Unit, Department of Experimental and Clinical Biochemical Sciences "Mario Serio", University of Florence, Florence, Italy
- Department of Gastroenterology, IBD Referral Center, Careggi University Hospital, Florence, Italy
| | - André D'Hoore
- Department of Abdominal Surgery, University Hospitals Leuven, Leuven, Belgium
| | - Gabriele Bislenghi
- Department of Abdominal Surgery, University Hospitals Leuven, Leuven, Belgium
| | - Stefano Scaringi
- Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
| | - Bram Verstockt
- Department of Chronic Diseases and Metabolism, Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven, Leuven, Belgium
- Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium
| | - Gert De Hertogh
- Laboratory of Translational Cell and Tissue Research, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium
| | - Kimberly Martinod
- Department of Cardiovascular Sciences, Center for Molecular and Vascular Biology, KU Leuven, Leuven, Belgium
| | - Andrea Galli
- Gastroenterology Research Unit, Department of Experimental and Clinical Biochemical Sciences "Mario Serio", University of Florence, Florence, Italy
- Department of Gastroenterology, IBD Referral Center, Careggi University Hospital, Florence, Italy
| | - Gianluca Matteoli
- Laboratory for Mucosal Immunology, Department of Chronic Diseases, Metabolism and Ageing, Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven, Leuven, Belgium
| | - Séverine Vermeire
- Department of Chronic Diseases and Metabolism, Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven, Leuven, Belgium
- Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium
| |
Collapse
|
3
|
Alyami AS, Madkhali Y, Majrashi NA, Alwadani B, Elbashir M, Ali S, Ageeli W, El-Bahkiry HS, Althobity AA, Refaee T. The role of molecular imaging in detecting fibrosis in Crohn's disease. Ann Med 2024; 56:2313676. [PMID: 38346385 PMCID: PMC10863520 DOI: 10.1080/07853890.2024.2313676] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/15/2023] [Accepted: 01/30/2024] [Indexed: 02/15/2024] Open
Abstract
Fibrosis is a pathological process that occurs due to chronic inflammation, leading to the proliferation of fibroblasts and the excessive deposition of extracellular matrix (ECM). The process of long-term fibrosis initiates with tissue hypofunction and progressively culminates in the ultimate manifestation of organ failure. Intestinal fibrosis is a significant complication of Crohn's disease (CD) that can result in persistent luminal narrowing and strictures, which are difficult to reverse. In recent years, there have been significant advances in our understanding of the cellular and molecular mechanisms underlying intestinal fibrosis in inflammatory bowel disease (IBD). Significant progress has been achieved in the fields of pathogenesis, diagnosis, and management of intestinal fibrosis in the last few years. A significant amount of research has also been conducted in the field of biomarkers for the prediction or detection of intestinal fibrosis, including novel cross-sectional imaging modalities such as positron emission tomography (PET) and single photon emission computed tomography (SPECT). Molecular imaging represents a promising biomedical approach that enables the non-invasive visualization of cellular and subcellular processes. Molecular imaging has the potential to be employed for early detection, disease staging, and prognostication in addition to assessing disease activity and treatment response in IBD. Molecular imaging methods also have a potential role to enabling minimally invasive assessment of intestinal fibrosis. This review discusses the role of molecular imaging in combination of AI in detecting CD fibrosis.
Collapse
Affiliation(s)
- Ali S. Alyami
- Department of Diagnostic Radiography Technology, College of Applied Medical Sciences, Jazan University, Jazan, Saudi Arabia
| | - Yahia Madkhali
- Department of Diagnostic Radiography Technology, College of Applied Medical Sciences, Jazan University, Jazan, Saudi Arabia
| | - Naif A. Majrashi
- Department of Diagnostic Radiography Technology, College of Applied Medical Sciences, Jazan University, Jazan, Saudi Arabia
| | - Bandar Alwadani
- Department of Diagnostic Radiography Technology, College of Applied Medical Sciences, Jazan University, Jazan, Saudi Arabia
| | - Meaad Elbashir
- Department of Diagnostic Radiography Technology, College of Applied Medical Sciences, Jazan University, Jazan, Saudi Arabia
| | - Sarra Ali
- Department of Diagnostic Radiography Technology, College of Applied Medical Sciences, Jazan University, Jazan, Saudi Arabia
| | - Wael Ageeli
- Department of Diagnostic Radiography Technology, College of Applied Medical Sciences, Jazan University, Jazan, Saudi Arabia
| | - Hesham S. El-Bahkiry
- Department of Diagnostic Radiography Technology, College of Applied Medical Sciences, Jazan University, Jazan, Saudi Arabia
| | - Abdullah A. Althobity
- Department of Radiological Sciences and Medical Imaging, College of Applied Medical Sciences, Majmaah University, Majmaah, Saudi Arabia
| | - Turkey Refaee
- Department of Diagnostic Radiography Technology, College of Applied Medical Sciences, Jazan University, Jazan, Saudi Arabia
| |
Collapse
|
4
|
Tavares de Sousa H, Ferreira M, Gullo I, Rocha AM, Pedro A, Leitão D, Oliveira C, Carneiro F, Magro F. Fibrosis-related Transcriptome Unveils a Distinctive Remodelling Matrix Pattern in Penetrating Ileal Crohn's Disease. J Crohns Colitis 2024; 18:1741-1752. [PMID: 38700484 DOI: 10.1093/ecco-jcc/jjae064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/30/2023] [Revised: 04/02/2024] [Accepted: 05/01/2024] [Indexed: 05/05/2024]
Abstract
BACKGROUND AND AIMS Stricturing [B2] and penetrating [B3] ileal Crohn's disease have been reported to present similar levels of histopathological transmural fibrosis. This study aimed to compare the fibrosis-related transcriptomic profiles of penetrating and stricturing ileal Crohn's disease. METHODS Using Nanostring technology and comparative bioinformatics, we analysed the expression of 787 fibrosis-related genes in 36 ileal surgical specimens, 12 B2 and 24 B3, the latter including 12 cases with associated stricture[s] [B3s] and 12 without [B3o]. Quality control of extracted RNA was performed according to Nanostring parameters and principal component analysis for the distribution analysis. For the selection of the differentially expressed genes, a p-adjusted <0.05 and fold change ≤-1.5 or ≥1.5 were adopted. Quantitative polymerase chain reaction (qPCR) and immunohistochemistry analyses were used to validate selected differentially expressed genes. RESULTS We included 34 patients with B2 and B3 phenotypes, balanced for age at diagnosis, age at surgery, gender, Crohn's disease localisation, perianal disease, and therapy. Inflammation and fibrosis histopathological scoring were similar in all cases. B2 and B3 groups showed a very good clustering regarding 30 significantly differentially expressed genes, all being remarkably upregulated in B3. More than half of these genes were involved in Crohn's disease fibrogenesis, and eight differentially expressed genes were so in other organs. The most significantly active biological processes and pathways in penetrating disease were response to TGFβ and matrix organisation and degradation, as validated by immunohistochemistry. CONCLUSIONS Despite the histopathological similarities in fibrosis between stricturing and penetrating ileal Crohn's disease, their fibrosis-related transcriptomic profiles are distinct. Penetrating disease exhibits a distinctive transcriptomic landscape related to enhanced matrix remodelling.
Collapse
Affiliation(s)
- Helena Tavares de Sousa
- Gastroenterology Department, Algarve University Hospital Center [CHUA], Portimão, Portugal
- ABC-Algarve Biomedical Center, University of Algarve, Faro, Portugal
| | - Marta Ferreira
- Computer Science Department, Faculty of Sciences, University of Porto, Porto, Portugal
- Institute of Molecular Pathology and Immunology, University of Porto [IPATIMUP], Porto, Portugal
- Instituto de Investigação e Inovação em Saúde [i3S], University of Porto, Porto, Portugal
| | - Irene Gullo
- Institute of Molecular Pathology and Immunology, University of Porto [IPATIMUP], Porto, Portugal
- Instituto de Investigação e Inovação em Saúde [i3S], University of Porto, Porto, Portugal
- Department of Pathology, Centro Hospitalar de São João, Porto, Portugal
- Department of Pathology, Faculty of Medicine of the University of Porto [FMUP], Porto, Portugal
| | - Ana Mafalda Rocha
- Institute of Molecular Pathology and Immunology, University of Porto [IPATIMUP], Porto, Portugal
- Instituto de Investigação e Inovação em Saúde [i3S], University of Porto, Porto, Portugal
| | - Ana Pedro
- Instituto de Investigação e Inovação em Saúde [i3S], University of Porto, Porto, Portugal
| | - Dina Leitão
- Department of Pathology, Faculty of Medicine of the University of Porto [FMUP], Porto, Portugal
| | - Carla Oliveira
- Institute of Molecular Pathology and Immunology, University of Porto [IPATIMUP], Porto, Portugal
- Instituto de Investigação e Inovação em Saúde [i3S], University of Porto, Porto, Portugal
- Department of Pathology, Centro Hospitalar de São João, Porto, Portugal
| | - Fátima Carneiro
- Institute of Molecular Pathology and Immunology, University of Porto [IPATIMUP], Porto, Portugal
- Instituto de Investigação e Inovação em Saúde [i3S], University of Porto, Porto, Portugal
- Department of Pathology, Centro Hospitalar de São João, Porto, Portugal
- Department of Pathology, Faculty of Medicine of the University of Porto [FMUP], Porto, Portugal
| | - Fernando Magro
- Unit of Pharmacology and Therapeutics, Department of Biomedicine, Faculty of Medicine of the University of Porto [FMUP], Portugal
- Department of Gastroenterology, São João University Hospital Center, Porto, Portugal
- CINTESIS@RISE, Faculty of Medicine, University of Porto, Porto, Portugal
| |
Collapse
|
5
|
Poulsen A, Ovesen PD, Lu C, Bettenworth D, Jairath V, Feagan BG, Seidelin JB, Rieder F. Serum Extracellular Matrix Molecules and Their Fragments as Biomarkers of Inflammation and Fibrosis in Inflammatory Bowel Diseases: A Systematic Review. J Crohns Colitis 2024; 18:1894-1934. [PMID: 38758527 DOI: 10.1093/ecco-jcc/jjae077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/22/2023] [Revised: 05/04/2024] [Accepted: 05/16/2024] [Indexed: 05/18/2024]
Abstract
BACKGROUND AND AIM Contemporary techniques to assess disease activity or bowel damage in patients with inflammatory bowel disease [IBD], such as endoscopy and imaging, are either invasive or lack accuracy. Non-invasive biomarkers for this purpose remain an unmet medical need. Herein, we provide a comprehensive systematic review of studies evaluating blood extracellular matrix [ECM] biomarkers and their relevance in IBD. METHODS We conducted a systematic review of PubMed, EMBASE, Web of Science, and Scopus to identify citations pertaining to ECM biomarkers of IBD up to March 1, 2024. Studies were categorized based on marker subtype and clinical use. RESULTS Thirty-one ECM markers were identified, 28 of which demonstrated the ability to differentiate IBD disease activity. Collagen III emerged as the most extensively investigated [1212 IBD patients], with the degradation marker C3M and deposition marker PRO-C3 being associated with IBD and subtypes. Collagen V markers C5M and PRO-C5 emerged as the most accurate single markers for diagnosis of IBD, with an area under the curve of 0.91 and 0.93, respectively. Overall, studies were characterized by variable endpoints. None of the studies included histological grading of intestinal damage, repair, or fibrosis formation as the primary outcome in relation to the ECM blood markers. CONCLUSIONS Multiple ECM markers are linked with IBD and its phenotypes. However, more rigorous study designs and clearly defined endpoints are needed to ensure reproducibility and develop reliable and accurate biomarkers. ECM markers hold promise as they provide a 'window' into transmural tissue remodelling and fibrosis burden, warranting further investigation.
Collapse
Affiliation(s)
- Anja Poulsen
- Digestive Disease Center, Bispebjerg Hospital, University of Copenhagen, Copenhagen NV, Denmark
- Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
| | - Pernille Dige Ovesen
- Department of Gastroenterology, Herlev Hospital, University of Copenhagen, Herlev, Denmark
| | - Cathy Lu
- Division of Gastroenterology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Dominik Bettenworth
- Medical Faculty, University of Münster, Münster, Germany
- CED Schwerpunktpraxis, Münster, Germany
| | - Vipul Jairath
- Division of Gastroenterology, Department of Medicine, Western University, London, ON N6A 3K7, Canada
- Department of Epidemiology and Biostatistics, Western University, London, ON N6A, Canada
| | - Brian G Feagan
- Division of Gastroenterology, Department of Medicine, Western University, London, ON N6A 3K7, Canada
- Department of Epidemiology and Biostatistics, Western University, London, ON N6A, Canada
- Alimentiv Inc, London, ON N6A 5B6, Canada
| | - Jakob Benedict Seidelin
- Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
- Department of Gastroenterology, Herlev Hospital, University of Copenhagen, Herlev, Denmark
| | - Florian Rieder
- Department of Inflammation and Immunity, Lerner Research Institute; Department of Gastroenterology, Hepatology and Nutrition, Digestive Diseases and Surgery Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
- Program for Global Translational Inflammatory Bowel Diseases, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
| |
Collapse
|
6
|
Chirra P, Sleiman J, Gandhi NS, Gordon IO, Hariri M, Baker M, Ottichilo R, Bruining DH, Kurowski JA, Viswanath SE, Rieder F. Radiomics to Detect Inflammation and Fibrosis on Magnetic Resonance Enterography in Stricturing Crohn's Disease. J Crohns Colitis 2024; 18:1660-1671. [PMID: 38761165 DOI: 10.1093/ecco-jcc/jjae073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/30/2023] [Revised: 04/07/2024] [Accepted: 05/13/2024] [Indexed: 05/20/2024]
Abstract
BACKGROUND AND AIMS Non-invasive cross-sectional imaging via magnetic resonance enterography [MRE] offers excellent accuracy for the diagnosis of stricturing complications in Crohn's disease [CD] but is limited in determining the degrees of fibrosis and inflammation within a stricture. We developed and validated a radiomics-based machine-learning model for separately characterizing the degree of histopathological inflammation and fibrosis in CD strictures and compared it to centrally read visual radiologist scoring of MRE. METHODS This single-centre, cross-sectional study included 51 CD patients [n = 34 for discovery; n = 17 for validation] with terminal ileal strictures confirmed on diagnostic MRE within 15 weeks of resection. Histopathological specimens were scored for inflammation and fibrosis and spatially linked with corresponding pre-surgical MRE sequences. Annotated stricture regions on MRE were scored visually by radiologists as well as underwent 3D radiomics-based machine learning analysis; both were evaluated against histopathology. RESULTS Two distinct sets of radiomic features capturing textural heterogeneity within strictures were linked with each of severe inflammation or severe fibrosis across both the discovery (area under the curve [AUC = 0.69, 0.83] and validation [AUC = 0.67, 0.78] cohorts. Radiologist visual scoring had an AUC = 0.67 for identifying severe inflammation and AUC = 0.35 for severe fibrosis. Use of combined radiomics and radiologist scoring robustly augmented identification of severe inflammation [AUC = 0.79] and modestly improved assessment of severe fibrosis [AUC = 0.79 for severe fibrosis] over individual approaches. CONCLUSIONS Radiomic features of CD strictures on MRE can accurately identify severe histopathological inflammation and severe histopathological fibrosis, as well as augment performance of the radiologist visual scoring in stricture characterization.
Collapse
Affiliation(s)
- Prathyush Chirra
- Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA
| | - Joseph Sleiman
- Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh School of Medicine, Pittsburgh Medical Center, Pittsburgh, PA, USA
| | - Namita S Gandhi
- Section, Abdominal Imaging, Imaging Institute, and Digestive Diseases and Surgery Institute and Cancer Institute, Cleveland Clinic, Cleveland, OH, USA
| | - Ilyssa O Gordon
- Department of Pathology, Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH, USA
| | - Mohsen Hariri
- Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA
| | - Mark Baker
- Section, Abdominal Imaging, Imaging Institute, and Digestive Diseases and Surgery Institute and Cancer Institute, Cleveland Clinic, Cleveland, OH, USA
| | - Ronald Ottichilo
- Department of Gastroenterology, Hepatology & Nutrition, Digestive Diseases and Surgery Institute, Cleveland Clinic, Cleveland, OH, USA
- Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA
| | - David H Bruining
- Division of Gastroenterology & Hepatology, Mayo Clinic, Rochester, MN, USA
| | - Jacob A Kurowski
- Department of Pediatric Gastroenterology, Hepatology & Nutrition, Cleveland Clinic, Cleveland, OH, USA
| | - Satish E Viswanath
- Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA
| | - Florian Rieder
- Department of Gastroenterology, Hepatology & Nutrition, Digestive Diseases and Surgery Institute, Cleveland Clinic, Cleveland, OH, USA
- Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA
- Center for Global Translational Inflammatory Bowel Disease Research, Cleveland Clinic, Cleveland, OH, USA
| |
Collapse
|
7
|
Geng Z, Li J, Zuo L, Zhang X, Wang L, Xia Y, Yang J, Yin L, Song X, Wang Y, Chai D, Deng M, Ge Y, Wu R, Hu J. Intestinal Adipocytes Transdifferentiate into Myofibroblast-like Cells and Contribute to Fibrosis in Crohn's Disease. J Crohns Colitis 2024; 18:1292-1304. [PMID: 38466138 DOI: 10.1093/ecco-jcc/jjae036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/29/2023] [Revised: 03/02/2024] [Accepted: 03/09/2024] [Indexed: 03/12/2024]
Abstract
BACKGROUND AND AIMS Intestinal fibrotic stenosis is a major reason for surgery in Crohn's disease [CD], but the mechanism is unknown. Thus, we asked whether intestinal adipocytes contribute to intestinal fibrosis. Adipocytes were found to transdifferentiate into myofibroblasts and confirmed to be involved in mesenteric fibrosis in our recent study. Here, we investigated the role and possible mechanisms of intestinal adipocytes in intestinal fibrosis in CD. METHODS The intestinal tissue of patients with CD with or without fibrotic stenosis [CDS or CDN] and normal intestinal tissue from individuals without CD were obtained to assess alterations in submucosal adipocytes in CDS and whether these cells transdifferentiated into myofibroblasts and participated in the fibrotic process. Human primary adipocytes and adipose organoids were used to evaluate whether adipocytes could be induced to transdifferentiate into myofibroblasts and to investigate the fibrotic behaviour of adipocytes. LPS/TLR4/TGF-β signalling was also studied to explore the underlying mechanism. RESULTS Submucosal adipocytes were reduced in number or even absent in CDS tissue, and the extent of the reduction correlated negatively with the degree of submucosal fibrosis. Interestingly, submucosal adipocytes in CDS tissue transdifferentiated into myofibroblast-like cells and expressed collagenous components, possibly due to stimulation by submucosally translocated bacteria. Lipopolysaccharide [LPS]-stimulated human primary adipocytes and adipose organoids also exhibited transdifferentiation and profibrotic behaviour. Mechanistically, TLR4-mediated TGF-β signalling was associated with the transdifferentiation and profibrotic behaviour of intestinal adipocytes in CDS tissue. CONCLUSIONS Intestinal adipocytes transdifferentiate into myofibroblasts and participate in the intestinal fibrosis process in CD, possibly through LPS/TLR4/TGF-β signalling.
Collapse
Affiliation(s)
- Zhijun Geng
- Department of Central Laboratory, First Affiliated Hospital of Bengbu Medical University, Bengbu, China
- Anhui Province Key Laboratory of Basic and Translational Research of Inflammation-related Diseases, Bengbu Medical University, Bengbu, China
- Inflammatory Bowel Disease Research Center, First Affiliated Hospital of Bengbu Medical University, Bengbu, China
| | - Jing Li
- Anhui Province Key Laboratory of Basic and Translational Research of Inflammation-related Diseases, Bengbu Medical University, Bengbu, China
- Inflammatory Bowel Disease Research Center, First Affiliated Hospital of Bengbu Medical University, Bengbu, China
- Department of Clinical Laboratory, First Affiliated Hospital of Bengbu Medical University, Bengbu, China
| | - Lugen Zuo
- Anhui Province Key Laboratory of Basic and Translational Research of Inflammation-related Diseases, Bengbu Medical University, Bengbu, China
- Inflammatory Bowel Disease Research Center, First Affiliated Hospital of Bengbu Medical University, Bengbu, China
- Department of Gastrointestinal Surgery, First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China
| | - Xiaofeng Zhang
- Department of Central Laboratory, First Affiliated Hospital of Bengbu Medical University, Bengbu, China
- Anhui Province Key Laboratory of Basic and Translational Research of Inflammation-related Diseases, Bengbu Medical University, Bengbu, China
- Inflammatory Bowel Disease Research Center, First Affiliated Hospital of Bengbu Medical University, Bengbu, China
| | - Lian Wang
- Anhui Province Key Laboratory of Basic and Translational Research of Inflammation-related Diseases, Bengbu Medical University, Bengbu, China
- Department of Gastrointestinal Surgery, First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China
| | - Yongsheng Xia
- Department of Gastrointestinal Surgery, First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China
| | - Jingjing Yang
- Department of Gastrointestinal Surgery, First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China
| | - Lixia Yin
- Department of Clinical Laboratory, First Affiliated Hospital of Bengbu Medical University, Bengbu, China
| | - Xue Song
- Department of Central Laboratory, First Affiliated Hospital of Bengbu Medical University, Bengbu, China
- Anhui Province Key Laboratory of Basic and Translational Research of Inflammation-related Diseases, Bengbu Medical University, Bengbu, China
- Inflammatory Bowel Disease Research Center, First Affiliated Hospital of Bengbu Medical University, Bengbu, China
| | - Yueyue Wang
- Anhui Province Key Laboratory of Basic and Translational Research of Inflammation-related Diseases, Bengbu Medical University, Bengbu, China
- Inflammatory Bowel Disease Research Center, First Affiliated Hospital of Bengbu Medical University, Bengbu, China
- Department of Clinical Laboratory, First Affiliated Hospital of Bengbu Medical University, Bengbu, China
| | - Damin Chai
- Anhui Province Key Laboratory of Basic and Translational Research of Inflammation-related Diseases, Bengbu Medical University, Bengbu, China
- Department of Pathology, First Affiliated Hospital of Bengbu Medical University, Bengbu, China
| | - Min Deng
- Anhui Province Key Laboratory of Basic and Translational Research of Inflammation-related Diseases, Bengbu Medical University, Bengbu, China
- Department of Gastroenterology, First Affiliated Hospital of Bengbu Medical University, Bengbu, China
| | - Yuanyuan Ge
- Department of Colorectal Surgery, Third Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China
| | - Rong Wu
- Department of General Surgery, Zhongda Hospital, Southeast University, Nanjing, China
| | - Jianguo Hu
- Anhui Province Key Laboratory of Basic and Translational Research of Inflammation-related Diseases, Bengbu Medical University, Bengbu, China
- Inflammatory Bowel Disease Research Center, First Affiliated Hospital of Bengbu Medical University, Bengbu, China
- Department of Clinical Laboratory, First Affiliated Hospital of Bengbu Medical University, Bengbu, China
| |
Collapse
|
8
|
Abdelhadi S, Tzatzarakis E, Hermann M, Orth V, Vedder K, Briscoe J, Reissfelder C, Șandra-Petrescu F. The impact of anastomotic leakage characteristics on the occurrence of anastomotic stenosis after colorectal resection, a retrospective cohort study. Int J Colorectal Dis 2024; 39:126. [PMID: 39105987 PMCID: PMC11303457 DOI: 10.1007/s00384-024-04699-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 07/23/2024] [Indexed: 08/07/2024]
Abstract
INTRODUCTION Anastomotic stenosis (AS) is a common complication after colorectal resection. However, the predisposing factors for stricture formation are not fully understood. Previous studies have shown anastomotic leakage (AL) to be a risk factor for the occurrence of AS. Therefore, we aim to investigate the impact of anastomotic leakage characteristics on the occurrence of anastomotic stenosis after colorectal resection. METHODS Consecutive patients with AL following elective, sphincter preserving, colorectal resection, with or without diversion ostomy, between January 2009 and March 2023 were identified from a prospectively collected database. The characteristics of the anastomotic leakage, patient baseline and operative characteristics as well as the postoperative outcomes were analyzed using univariate and multivariate logistic regression to identify factors associated with the occurrence of post-leakage AS. RESULTS A total of 129 patients developed AL and met the inclusion criteria. Among these, 28 (21.7%) patients were diagnosed with post-leakage AS. There was a significantly higher frequency of patients with neoadjuvant radiotherapy (18% vs 3%; p = .026) and hand-sewn anastomoses (39% vs 17%; p = .011) within the AS group. Furthermore, the extent of the anastomotic defect was significantly higher in the AS group compared with the non-AS group (50%, IQR 27-71 vs. 20%, IQR 9-40, p = 0.011). Similar findings were observed between the study groups regarding age, sex, BMI, ASA score, medical comorbidities, diagnosis, surgical procedure, surgical approach (open vs. minimally invasive), and anastomotic fashioning (side-to-end vs. end-to-end). On multivariate analysis, the extent of the anastomotic defect (OR 1.01; 95% CI 1.00-1.03; p = 0.034) and hand-sewn anastomoses (OR 2.68; 95% CI 1.01-6.98; p = 0.043) were confirmed as independent risk factors for post-leakage AS. No correlation could be observed between the occurrence of post-leakage AS and the ISREC grading of AL, the anastomotic height or the management of AL. Time to ostomy reversal was significantly longer in the AS group (202d, IQR 169-275 vs. 318d IQR 192-416, p = 0.014). CONCLUSION The extent of the anastomotic defect and hand-sewn anastomoses were confirmed as independent risk factors for the occurrence of post-leakage AS. No correlation could be observed between the ISREC grading of AL, the anastomotic height or AL management, and the occurrence of post-leakage AS.
Collapse
Affiliation(s)
- Schaima Abdelhadi
- Department of Surgery, Medical Faculty Mannheim, Universitätsmedizin Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany
| | - Emmanouil Tzatzarakis
- Department of Surgery, Medical Faculty Mannheim, Universitätsmedizin Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany
| | - Maike Hermann
- Department of Surgery, Medical Faculty Mannheim, Universitätsmedizin Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany
| | - Vanessa Orth
- Department of Surgery, Medical Faculty Mannheim, Universitätsmedizin Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany
| | - Katharina Vedder
- Department of Surgery, Medical Faculty Mannheim, Universitätsmedizin Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany
| | - Jannis Briscoe
- Department of Surgery, Medical Faculty Mannheim, Universitätsmedizin Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany
| | - Christoph Reissfelder
- Department of Surgery, Medical Faculty Mannheim, Universitätsmedizin Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany
- DKFZ Hector Cancer Institute at the University Medical Center, Mannheim, Germany
| | - Flavius Șandra-Petrescu
- Department of Surgery, Medical Faculty Mannheim, Universitätsmedizin Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.
| |
Collapse
|
9
|
Bettenworth D, Baker ME, Fletcher JG, Jairath V, Lu C, Bemelman W, d'Haens G, d'Hoore A, Dignass A, Dotan I, Feakins R, Fleshner P, Ha C, Henderson G, Lyu R, Panes J, Rogler G, Mao R, Rimola J, Sandborn WJ, Ng SC, Siegmund B, Silverberg M, Taylor SA, Verstockt B, Gordon IO, Bruining DH, Feagan BG, Rieder F. A global consensus on the definitions, diagnosis and management of fibrostenosing small bowel Crohn's disease in clinical practice. Nat Rev Gastroenterol Hepatol 2024; 21:572-584. [PMID: 38831007 DOI: 10.1038/s41575-024-00935-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 04/19/2024] [Indexed: 06/05/2024]
Abstract
Fibrostenosis of the small bowel is common in patients with Crohn's disease. No consensus recommendations on definition, diagnosis and management in clinical practice are currently available. In this Consensus Statement, we present a clinical practice RAND/UCLA appropriateness study on the definition, diagnosis and clinical management of fibrostenosing Crohn's disease. It was conducted by a panel of 28 global experts and one patient representative. Following a systematic literature review, 526 candidate items grouped into 136 questions were generated and subsequently evaluated for appropriateness. Strictures are best defined as wall thickening, luminal narrowing and prestenotic dilation. Cross-sectional imaging is required for accurate diagnosis of fibrostenosing Crohn's disease, and it is recommended before making treatment decisions. It should also assess the degree of inflammation in the bowel wall. Multiple options for medical anti-inflammatory, endoscopic and surgical therapies were suggested, including follow-up strategies following therapy. This Consensus Statement supports clinical practice through providing guidance on definitions, diagnosis and therapeutic management of patients with fibrostenosing small bowel Crohn's disease.
Collapse
Affiliation(s)
- Dominik Bettenworth
- CED Schwerpunktpraxis, Münster, Germany.
- Medical Faculty, University of Münster, Münster, Germany.
| | - Mark E Baker
- Diagnostic Radiology, Imaging Institute, Cleveland Clinic, Cleveland, OH, USA
| | | | - Vipul Jairath
- Alimentiv Inc, London, Ontario, Canada
- Department of Medicine, Western University, London, Ontario, Canada
- Department of Biostatistics and Epidemiology, Western University, London, Ontario, Canada
| | - Cathy Lu
- Division of Gastroenterology and Hepatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Willem Bemelman
- Department of Surgery, Amsterdam University Medical Centers, Amsterdam, Netherlands
| | - Geert d'Haens
- Department of Gastroenterology, Amsterdam University Medical Centers, Amsterdam, Netherlands
| | - Andre d'Hoore
- Department of Abdominal Surgery, University Hospitals Leuven, Leuven, Belgium
| | - Axel Dignass
- Department of Medicine I, Agaplesion Markus Hospital, Goethe University, Frankfurt am Main, Germany
| | - Iris Dotan
- Division of Gastroenterology, Rabin Medical Center, Petah-Tikva, Israel
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Roger Feakins
- Department of Cellular Pathology, Royal Free London NHS Foundation Trust, London, UK
| | - Phillip Fleshner
- Division of Colon and Rectal Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Christina Ha
- Department of Gastroenterology, Mayo Clinic Arizona, Scottsdale, AZ, USA
| | | | - Ruishen Lyu
- Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA
| | - Julian Panes
- Department of Gastroenterology, Hospital Clinic of Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain
| | - Gerhard Rogler
- Department of Gastroenterology and Hepatology, University Hospital, Zurich, University of Zurich, Zurich, Switzerland
| | - Ren Mao
- Department of Gastroenterology and Hepatology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
| | - Jordi Rimola
- Inflammatory bowel disease unit, Department of Radiology, Hospital Clínic de Barcelona, Barcelona, IDIBAPS, Barcelona, Spain
| | - William J Sandborn
- Division of Gastroenterology and Hepatology, University of California San Diego, La Jolla, CA, USA
| | - Siew C Ng
- Division of Gastroenterology and Hepatology, State Key Laboratory of Digestive Diseases, The Chinese University of Hong Kong, Hong Kong, China
| | - Britta Siegmund
- Division of Gastroenterology, Infectiology and Rheumatology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
| | - Mark Silverberg
- Division of Gastroenterology, Mount Sinai Hospital, Toronto, Canada
| | - Stuart A Taylor
- Centre for Medical Imaging, University College London, London, UK
| | - Bram Verstockt
- Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium
- Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium
| | - Ilyssa O Gordon
- Department of Anatomic Pathology, Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic Foundation, Cleveland, OH, USA
| | - David H Bruining
- Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN, USA
| | - Brian G Feagan
- Alimentiv Inc, London, Ontario, Canada
- Department of Medicine, Western University, London, Ontario, Canada
- Department of Biostatistics and Epidemiology, Western University, London, Ontario, Canada
| | - Florian Rieder
- Department of Gastroenterology, Hepatology and Nutrition, Digestive Diseases and Surgery Institute, Cleveland Clinic Foundation, Cleveland, OH, USA
- Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, USA
- Center for Global Translational Inflammatory Bowel Disease Research, Cleveland Clinic, Cleveland, OH, USA
| |
Collapse
|
10
|
Rieder F, Ma C, Hanzel J, Fletcher JG, Baker ME, Wang Z, Guizzetti L, Shackelton LM, Rémillard J, Patel M, Niu J, Ottichilo R, Santillan CS, Capozzi N, Taylor SA, Bruining DH, Zou G, Feagan BG, Jairath V, Rimola J, Atzen S. Reliability of CT Enterography for Describing Fibrostenosing Crohn Disease. Radiology 2024; 312:e233038. [PMID: 39105638 PMCID: PMC11366669 DOI: 10.1148/radiol.233038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2023] [Revised: 04/12/2024] [Accepted: 04/23/2024] [Indexed: 08/07/2024]
Abstract
Background Standardized methods to measure and describe Crohn disease strictures at CT enterography are needed to guide clinical decision making and for use in therapeutic studies. Purpose To assess the reliability of CT enterography features to describe Crohn disease strictures and their correlation with stricture severity. Materials and Methods A retrospective study was conducted in 43 adult patients with symptomatic terminal ileal Crohn disease strictures who underwent standard-of-care CT enterography at a tertiary care center at the Cleveland Clinic between January 2008 and August 2016. After training on standardized definitions, four abdominal radiologists blinded to all patient information assessed imaging features (seven continuous measurements and nine observations) of the most distal ileal stricture in two separate sessions (separated by ≥2 weeks) in random order. Features with an interrater intraclass correlation coefficient (ICC) of 0.41 or greater (ie, moderate reliability or better) were considered reliable. Univariable and multivariable linear regression analysis identified reliable features associated with a visual analog scale of overall stricture severity. Significant reliable features were assessed as components of a CT enterography-based model to quantitate stricture severity. Results Examinations in 43 patients (mean age, 52 years ± 16 [SD]; 23 female) were evaluated. Five continuous measurements and six observations demonstrated at least moderate interrater reliability (interrater ICC range, 0.42 [95% CI: 0.25, 0.57] to 0.80 [95% CI: 0.67, 0.88]). Of these, 10 were univariably associated with stricture severity, and three continuous measurements-stricture length (interrater ICC, 0.64 [95% CI: 0.42, 0.81]), maximal associated small bowel dilation (interrater ICC, 0.80 [95% CI: 0.67, 0.88]), and maximal stricture wall thickness (interrater ICC, 0.50 [95% CI: 0.34, 0.62])-were independently associated (P value range, <.001 to .003) with stricture severity in a multivariable model. These three measurements were used to derive a well-calibrated (optimism-adjusted calibration slope = 1.00) quantitative model of stricture severity. Conclusion Standardized CT enterography measurements and observations can reliably describe terminal ileal Crohn disease strictures. Stricture length, maximal associated small bowel dilation, and maximal stricture wall thickness are correlated with stricture severity. © RSNA, 2024 Supplemental material is available for this article. See also the article by Rieder et al in this issue. See also the editorial by Galgano and Summerlin in this issue.
Collapse
Affiliation(s)
| | | | - Jurij Hanzel
- From the Department of Inflammation and Immunity, Lerner Research
Institute, Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH 44195 (F.R.);
Department of Gastroenterology, Hepatology, and Nutrition, Digestive Diseases
and Surgery Institute and Program for Global Translational Inflammatory Bowel
Diseases Research, Cleveland Clinic, Cleveland, Ohio (F.R., M.P., J.N., R.O.);
Departments of Medicine and Community Health Sciences, Division of
Gastroenterology and Hepatology, University of Calgary, Calgary, Alberta, Canada
(C.M.); Alimentiv, London, Ontario, Canada (C.M., J.H., Z.W., L.G., L.M.S., J.
Rémillard, G.Z., B.G.F., V.J.); Department of Gastroenterology,
University of Ljubljana, University Medical Centre Ljubljana, Ljubljana,
Slovenia (J.H.); Department of Radiology, Mayo Clinic, Rochester, Minn (J.G.F.);
Section of Abdominal Imaging, Imaging Institute, Digestive Diseases and Surgery
Institute and Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio
(M.E.B.); Department of Radiology, University of California San Diego, San
Diego, Calif (C.S.S.); Department of Radiology, IBD Unit, Hospital Clínic
de Barcelona, Barcelona, Spain (N.C., J. Rimola); Pediatric and Adult
Cardiothoracic and Vascular, Oncohematologic and Emergency Radiology Unit, IRCCS
Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy (N.C.); Centre for
Medical Imaging, University College London, London, England (S.A.T.); Division
of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science,
Rochester, Minn (D.H.B.); and Departments of Medicine and Epidemiology and
Biostatistics, Schulich School of Medicine and Dentistry, University of Western
Ontario, London, Ontario, Canada (B.G.F., V.J.)
| | - Joel G. Fletcher
- From the Department of Inflammation and Immunity, Lerner Research
Institute, Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH 44195 (F.R.);
Department of Gastroenterology, Hepatology, and Nutrition, Digestive Diseases
and Surgery Institute and Program for Global Translational Inflammatory Bowel
Diseases Research, Cleveland Clinic, Cleveland, Ohio (F.R., M.P., J.N., R.O.);
Departments of Medicine and Community Health Sciences, Division of
Gastroenterology and Hepatology, University of Calgary, Calgary, Alberta, Canada
(C.M.); Alimentiv, London, Ontario, Canada (C.M., J.H., Z.W., L.G., L.M.S., J.
Rémillard, G.Z., B.G.F., V.J.); Department of Gastroenterology,
University of Ljubljana, University Medical Centre Ljubljana, Ljubljana,
Slovenia (J.H.); Department of Radiology, Mayo Clinic, Rochester, Minn (J.G.F.);
Section of Abdominal Imaging, Imaging Institute, Digestive Diseases and Surgery
Institute and Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio
(M.E.B.); Department of Radiology, University of California San Diego, San
Diego, Calif (C.S.S.); Department of Radiology, IBD Unit, Hospital Clínic
de Barcelona, Barcelona, Spain (N.C., J. Rimola); Pediatric and Adult
Cardiothoracic and Vascular, Oncohematologic and Emergency Radiology Unit, IRCCS
Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy (N.C.); Centre for
Medical Imaging, University College London, London, England (S.A.T.); Division
of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science,
Rochester, Minn (D.H.B.); and Departments of Medicine and Epidemiology and
Biostatistics, Schulich School of Medicine and Dentistry, University of Western
Ontario, London, Ontario, Canada (B.G.F., V.J.)
| | - Mark E. Baker
- From the Department of Inflammation and Immunity, Lerner Research
Institute, Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH 44195 (F.R.);
Department of Gastroenterology, Hepatology, and Nutrition, Digestive Diseases
and Surgery Institute and Program for Global Translational Inflammatory Bowel
Diseases Research, Cleveland Clinic, Cleveland, Ohio (F.R., M.P., J.N., R.O.);
Departments of Medicine and Community Health Sciences, Division of
Gastroenterology and Hepatology, University of Calgary, Calgary, Alberta, Canada
(C.M.); Alimentiv, London, Ontario, Canada (C.M., J.H., Z.W., L.G., L.M.S., J.
Rémillard, G.Z., B.G.F., V.J.); Department of Gastroenterology,
University of Ljubljana, University Medical Centre Ljubljana, Ljubljana,
Slovenia (J.H.); Department of Radiology, Mayo Clinic, Rochester, Minn (J.G.F.);
Section of Abdominal Imaging, Imaging Institute, Digestive Diseases and Surgery
Institute and Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio
(M.E.B.); Department of Radiology, University of California San Diego, San
Diego, Calif (C.S.S.); Department of Radiology, IBD Unit, Hospital Clínic
de Barcelona, Barcelona, Spain (N.C., J. Rimola); Pediatric and Adult
Cardiothoracic and Vascular, Oncohematologic and Emergency Radiology Unit, IRCCS
Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy (N.C.); Centre for
Medical Imaging, University College London, London, England (S.A.T.); Division
of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science,
Rochester, Minn (D.H.B.); and Departments of Medicine and Epidemiology and
Biostatistics, Schulich School of Medicine and Dentistry, University of Western
Ontario, London, Ontario, Canada (B.G.F., V.J.)
| | - Zhongya Wang
- From the Department of Inflammation and Immunity, Lerner Research
Institute, Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH 44195 (F.R.);
Department of Gastroenterology, Hepatology, and Nutrition, Digestive Diseases
and Surgery Institute and Program for Global Translational Inflammatory Bowel
Diseases Research, Cleveland Clinic, Cleveland, Ohio (F.R., M.P., J.N., R.O.);
Departments of Medicine and Community Health Sciences, Division of
Gastroenterology and Hepatology, University of Calgary, Calgary, Alberta, Canada
(C.M.); Alimentiv, London, Ontario, Canada (C.M., J.H., Z.W., L.G., L.M.S., J.
Rémillard, G.Z., B.G.F., V.J.); Department of Gastroenterology,
University of Ljubljana, University Medical Centre Ljubljana, Ljubljana,
Slovenia (J.H.); Department of Radiology, Mayo Clinic, Rochester, Minn (J.G.F.);
Section of Abdominal Imaging, Imaging Institute, Digestive Diseases and Surgery
Institute and Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio
(M.E.B.); Department of Radiology, University of California San Diego, San
Diego, Calif (C.S.S.); Department of Radiology, IBD Unit, Hospital Clínic
de Barcelona, Barcelona, Spain (N.C., J. Rimola); Pediatric and Adult
Cardiothoracic and Vascular, Oncohematologic and Emergency Radiology Unit, IRCCS
Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy (N.C.); Centre for
Medical Imaging, University College London, London, England (S.A.T.); Division
of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science,
Rochester, Minn (D.H.B.); and Departments of Medicine and Epidemiology and
Biostatistics, Schulich School of Medicine and Dentistry, University of Western
Ontario, London, Ontario, Canada (B.G.F., V.J.)
| | - Leonardo Guizzetti
- From the Department of Inflammation and Immunity, Lerner Research
Institute, Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH 44195 (F.R.);
Department of Gastroenterology, Hepatology, and Nutrition, Digestive Diseases
and Surgery Institute and Program for Global Translational Inflammatory Bowel
Diseases Research, Cleveland Clinic, Cleveland, Ohio (F.R., M.P., J.N., R.O.);
Departments of Medicine and Community Health Sciences, Division of
Gastroenterology and Hepatology, University of Calgary, Calgary, Alberta, Canada
(C.M.); Alimentiv, London, Ontario, Canada (C.M., J.H., Z.W., L.G., L.M.S., J.
Rémillard, G.Z., B.G.F., V.J.); Department of Gastroenterology,
University of Ljubljana, University Medical Centre Ljubljana, Ljubljana,
Slovenia (J.H.); Department of Radiology, Mayo Clinic, Rochester, Minn (J.G.F.);
Section of Abdominal Imaging, Imaging Institute, Digestive Diseases and Surgery
Institute and Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio
(M.E.B.); Department of Radiology, University of California San Diego, San
Diego, Calif (C.S.S.); Department of Radiology, IBD Unit, Hospital Clínic
de Barcelona, Barcelona, Spain (N.C., J. Rimola); Pediatric and Adult
Cardiothoracic and Vascular, Oncohematologic and Emergency Radiology Unit, IRCCS
Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy (N.C.); Centre for
Medical Imaging, University College London, London, England (S.A.T.); Division
of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science,
Rochester, Minn (D.H.B.); and Departments of Medicine and Epidemiology and
Biostatistics, Schulich School of Medicine and Dentistry, University of Western
Ontario, London, Ontario, Canada (B.G.F., V.J.)
| | - Lisa M. Shackelton
- From the Department of Inflammation and Immunity, Lerner Research
Institute, Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH 44195 (F.R.);
Department of Gastroenterology, Hepatology, and Nutrition, Digestive Diseases
and Surgery Institute and Program for Global Translational Inflammatory Bowel
Diseases Research, Cleveland Clinic, Cleveland, Ohio (F.R., M.P., J.N., R.O.);
Departments of Medicine and Community Health Sciences, Division of
Gastroenterology and Hepatology, University of Calgary, Calgary, Alberta, Canada
(C.M.); Alimentiv, London, Ontario, Canada (C.M., J.H., Z.W., L.G., L.M.S., J.
Rémillard, G.Z., B.G.F., V.J.); Department of Gastroenterology,
University of Ljubljana, University Medical Centre Ljubljana, Ljubljana,
Slovenia (J.H.); Department of Radiology, Mayo Clinic, Rochester, Minn (J.G.F.);
Section of Abdominal Imaging, Imaging Institute, Digestive Diseases and Surgery
Institute and Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio
(M.E.B.); Department of Radiology, University of California San Diego, San
Diego, Calif (C.S.S.); Department of Radiology, IBD Unit, Hospital Clínic
de Barcelona, Barcelona, Spain (N.C., J. Rimola); Pediatric and Adult
Cardiothoracic and Vascular, Oncohematologic and Emergency Radiology Unit, IRCCS
Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy (N.C.); Centre for
Medical Imaging, University College London, London, England (S.A.T.); Division
of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science,
Rochester, Minn (D.H.B.); and Departments of Medicine and Epidemiology and
Biostatistics, Schulich School of Medicine and Dentistry, University of Western
Ontario, London, Ontario, Canada (B.G.F., V.J.)
| | - Julie Rémillard
- From the Department of Inflammation and Immunity, Lerner Research
Institute, Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH 44195 (F.R.);
Department of Gastroenterology, Hepatology, and Nutrition, Digestive Diseases
and Surgery Institute and Program for Global Translational Inflammatory Bowel
Diseases Research, Cleveland Clinic, Cleveland, Ohio (F.R., M.P., J.N., R.O.);
Departments of Medicine and Community Health Sciences, Division of
Gastroenterology and Hepatology, University of Calgary, Calgary, Alberta, Canada
(C.M.); Alimentiv, London, Ontario, Canada (C.M., J.H., Z.W., L.G., L.M.S., J.
Rémillard, G.Z., B.G.F., V.J.); Department of Gastroenterology,
University of Ljubljana, University Medical Centre Ljubljana, Ljubljana,
Slovenia (J.H.); Department of Radiology, Mayo Clinic, Rochester, Minn (J.G.F.);
Section of Abdominal Imaging, Imaging Institute, Digestive Diseases and Surgery
Institute and Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio
(M.E.B.); Department of Radiology, University of California San Diego, San
Diego, Calif (C.S.S.); Department of Radiology, IBD Unit, Hospital Clínic
de Barcelona, Barcelona, Spain (N.C., J. Rimola); Pediatric and Adult
Cardiothoracic and Vascular, Oncohematologic and Emergency Radiology Unit, IRCCS
Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy (N.C.); Centre for
Medical Imaging, University College London, London, England (S.A.T.); Division
of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science,
Rochester, Minn (D.H.B.); and Departments of Medicine and Epidemiology and
Biostatistics, Schulich School of Medicine and Dentistry, University of Western
Ontario, London, Ontario, Canada (B.G.F., V.J.)
| | - Mihir Patel
- From the Department of Inflammation and Immunity, Lerner Research
Institute, Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH 44195 (F.R.);
Department of Gastroenterology, Hepatology, and Nutrition, Digestive Diseases
and Surgery Institute and Program for Global Translational Inflammatory Bowel
Diseases Research, Cleveland Clinic, Cleveland, Ohio (F.R., M.P., J.N., R.O.);
Departments of Medicine and Community Health Sciences, Division of
Gastroenterology and Hepatology, University of Calgary, Calgary, Alberta, Canada
(C.M.); Alimentiv, London, Ontario, Canada (C.M., J.H., Z.W., L.G., L.M.S., J.
Rémillard, G.Z., B.G.F., V.J.); Department of Gastroenterology,
University of Ljubljana, University Medical Centre Ljubljana, Ljubljana,
Slovenia (J.H.); Department of Radiology, Mayo Clinic, Rochester, Minn (J.G.F.);
Section of Abdominal Imaging, Imaging Institute, Digestive Diseases and Surgery
Institute and Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio
(M.E.B.); Department of Radiology, University of California San Diego, San
Diego, Calif (C.S.S.); Department of Radiology, IBD Unit, Hospital Clínic
de Barcelona, Barcelona, Spain (N.C., J. Rimola); Pediatric and Adult
Cardiothoracic and Vascular, Oncohematologic and Emergency Radiology Unit, IRCCS
Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy (N.C.); Centre for
Medical Imaging, University College London, London, England (S.A.T.); Division
of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science,
Rochester, Minn (D.H.B.); and Departments of Medicine and Epidemiology and
Biostatistics, Schulich School of Medicine and Dentistry, University of Western
Ontario, London, Ontario, Canada (B.G.F., V.J.)
| | - Jiafei Niu
- From the Department of Inflammation and Immunity, Lerner Research
Institute, Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH 44195 (F.R.);
Department of Gastroenterology, Hepatology, and Nutrition, Digestive Diseases
and Surgery Institute and Program for Global Translational Inflammatory Bowel
Diseases Research, Cleveland Clinic, Cleveland, Ohio (F.R., M.P., J.N., R.O.);
Departments of Medicine and Community Health Sciences, Division of
Gastroenterology and Hepatology, University of Calgary, Calgary, Alberta, Canada
(C.M.); Alimentiv, London, Ontario, Canada (C.M., J.H., Z.W., L.G., L.M.S., J.
Rémillard, G.Z., B.G.F., V.J.); Department of Gastroenterology,
University of Ljubljana, University Medical Centre Ljubljana, Ljubljana,
Slovenia (J.H.); Department of Radiology, Mayo Clinic, Rochester, Minn (J.G.F.);
Section of Abdominal Imaging, Imaging Institute, Digestive Diseases and Surgery
Institute and Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio
(M.E.B.); Department of Radiology, University of California San Diego, San
Diego, Calif (C.S.S.); Department of Radiology, IBD Unit, Hospital Clínic
de Barcelona, Barcelona, Spain (N.C., J. Rimola); Pediatric and Adult
Cardiothoracic and Vascular, Oncohematologic and Emergency Radiology Unit, IRCCS
Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy (N.C.); Centre for
Medical Imaging, University College London, London, England (S.A.T.); Division
of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science,
Rochester, Minn (D.H.B.); and Departments of Medicine and Epidemiology and
Biostatistics, Schulich School of Medicine and Dentistry, University of Western
Ontario, London, Ontario, Canada (B.G.F., V.J.)
| | - Ronald Ottichilo
- From the Department of Inflammation and Immunity, Lerner Research
Institute, Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH 44195 (F.R.);
Department of Gastroenterology, Hepatology, and Nutrition, Digestive Diseases
and Surgery Institute and Program for Global Translational Inflammatory Bowel
Diseases Research, Cleveland Clinic, Cleveland, Ohio (F.R., M.P., J.N., R.O.);
Departments of Medicine and Community Health Sciences, Division of
Gastroenterology and Hepatology, University of Calgary, Calgary, Alberta, Canada
(C.M.); Alimentiv, London, Ontario, Canada (C.M., J.H., Z.W., L.G., L.M.S., J.
Rémillard, G.Z., B.G.F., V.J.); Department of Gastroenterology,
University of Ljubljana, University Medical Centre Ljubljana, Ljubljana,
Slovenia (J.H.); Department of Radiology, Mayo Clinic, Rochester, Minn (J.G.F.);
Section of Abdominal Imaging, Imaging Institute, Digestive Diseases and Surgery
Institute and Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio
(M.E.B.); Department of Radiology, University of California San Diego, San
Diego, Calif (C.S.S.); Department of Radiology, IBD Unit, Hospital Clínic
de Barcelona, Barcelona, Spain (N.C., J. Rimola); Pediatric and Adult
Cardiothoracic and Vascular, Oncohematologic and Emergency Radiology Unit, IRCCS
Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy (N.C.); Centre for
Medical Imaging, University College London, London, England (S.A.T.); Division
of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science,
Rochester, Minn (D.H.B.); and Departments of Medicine and Epidemiology and
Biostatistics, Schulich School of Medicine and Dentistry, University of Western
Ontario, London, Ontario, Canada (B.G.F., V.J.)
| | - Cynthia S. Santillan
- From the Department of Inflammation and Immunity, Lerner Research
Institute, Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH 44195 (F.R.);
Department of Gastroenterology, Hepatology, and Nutrition, Digestive Diseases
and Surgery Institute and Program for Global Translational Inflammatory Bowel
Diseases Research, Cleveland Clinic, Cleveland, Ohio (F.R., M.P., J.N., R.O.);
Departments of Medicine and Community Health Sciences, Division of
Gastroenterology and Hepatology, University of Calgary, Calgary, Alberta, Canada
(C.M.); Alimentiv, London, Ontario, Canada (C.M., J.H., Z.W., L.G., L.M.S., J.
Rémillard, G.Z., B.G.F., V.J.); Department of Gastroenterology,
University of Ljubljana, University Medical Centre Ljubljana, Ljubljana,
Slovenia (J.H.); Department of Radiology, Mayo Clinic, Rochester, Minn (J.G.F.);
Section of Abdominal Imaging, Imaging Institute, Digestive Diseases and Surgery
Institute and Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio
(M.E.B.); Department of Radiology, University of California San Diego, San
Diego, Calif (C.S.S.); Department of Radiology, IBD Unit, Hospital Clínic
de Barcelona, Barcelona, Spain (N.C., J. Rimola); Pediatric and Adult
Cardiothoracic and Vascular, Oncohematologic and Emergency Radiology Unit, IRCCS
Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy (N.C.); Centre for
Medical Imaging, University College London, London, England (S.A.T.); Division
of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science,
Rochester, Minn (D.H.B.); and Departments of Medicine and Epidemiology and
Biostatistics, Schulich School of Medicine and Dentistry, University of Western
Ontario, London, Ontario, Canada (B.G.F., V.J.)
| | - Nunzia Capozzi
- From the Department of Inflammation and Immunity, Lerner Research
Institute, Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH 44195 (F.R.);
Department of Gastroenterology, Hepatology, and Nutrition, Digestive Diseases
and Surgery Institute and Program for Global Translational Inflammatory Bowel
Diseases Research, Cleveland Clinic, Cleveland, Ohio (F.R., M.P., J.N., R.O.);
Departments of Medicine and Community Health Sciences, Division of
Gastroenterology and Hepatology, University of Calgary, Calgary, Alberta, Canada
(C.M.); Alimentiv, London, Ontario, Canada (C.M., J.H., Z.W., L.G., L.M.S., J.
Rémillard, G.Z., B.G.F., V.J.); Department of Gastroenterology,
University of Ljubljana, University Medical Centre Ljubljana, Ljubljana,
Slovenia (J.H.); Department of Radiology, Mayo Clinic, Rochester, Minn (J.G.F.);
Section of Abdominal Imaging, Imaging Institute, Digestive Diseases and Surgery
Institute and Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio
(M.E.B.); Department of Radiology, University of California San Diego, San
Diego, Calif (C.S.S.); Department of Radiology, IBD Unit, Hospital Clínic
de Barcelona, Barcelona, Spain (N.C., J. Rimola); Pediatric and Adult
Cardiothoracic and Vascular, Oncohematologic and Emergency Radiology Unit, IRCCS
Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy (N.C.); Centre for
Medical Imaging, University College London, London, England (S.A.T.); Division
of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science,
Rochester, Minn (D.H.B.); and Departments of Medicine and Epidemiology and
Biostatistics, Schulich School of Medicine and Dentistry, University of Western
Ontario, London, Ontario, Canada (B.G.F., V.J.)
| | - Stuart A. Taylor
- From the Department of Inflammation and Immunity, Lerner Research
Institute, Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH 44195 (F.R.);
Department of Gastroenterology, Hepatology, and Nutrition, Digestive Diseases
and Surgery Institute and Program for Global Translational Inflammatory Bowel
Diseases Research, Cleveland Clinic, Cleveland, Ohio (F.R., M.P., J.N., R.O.);
Departments of Medicine and Community Health Sciences, Division of
Gastroenterology and Hepatology, University of Calgary, Calgary, Alberta, Canada
(C.M.); Alimentiv, London, Ontario, Canada (C.M., J.H., Z.W., L.G., L.M.S., J.
Rémillard, G.Z., B.G.F., V.J.); Department of Gastroenterology,
University of Ljubljana, University Medical Centre Ljubljana, Ljubljana,
Slovenia (J.H.); Department of Radiology, Mayo Clinic, Rochester, Minn (J.G.F.);
Section of Abdominal Imaging, Imaging Institute, Digestive Diseases and Surgery
Institute and Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio
(M.E.B.); Department of Radiology, University of California San Diego, San
Diego, Calif (C.S.S.); Department of Radiology, IBD Unit, Hospital Clínic
de Barcelona, Barcelona, Spain (N.C., J. Rimola); Pediatric and Adult
Cardiothoracic and Vascular, Oncohematologic and Emergency Radiology Unit, IRCCS
Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy (N.C.); Centre for
Medical Imaging, University College London, London, England (S.A.T.); Division
of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science,
Rochester, Minn (D.H.B.); and Departments of Medicine and Epidemiology and
Biostatistics, Schulich School of Medicine and Dentistry, University of Western
Ontario, London, Ontario, Canada (B.G.F., V.J.)
| | - David H. Bruining
- From the Department of Inflammation and Immunity, Lerner Research
Institute, Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH 44195 (F.R.);
Department of Gastroenterology, Hepatology, and Nutrition, Digestive Diseases
and Surgery Institute and Program for Global Translational Inflammatory Bowel
Diseases Research, Cleveland Clinic, Cleveland, Ohio (F.R., M.P., J.N., R.O.);
Departments of Medicine and Community Health Sciences, Division of
Gastroenterology and Hepatology, University of Calgary, Calgary, Alberta, Canada
(C.M.); Alimentiv, London, Ontario, Canada (C.M., J.H., Z.W., L.G., L.M.S., J.
Rémillard, G.Z., B.G.F., V.J.); Department of Gastroenterology,
University of Ljubljana, University Medical Centre Ljubljana, Ljubljana,
Slovenia (J.H.); Department of Radiology, Mayo Clinic, Rochester, Minn (J.G.F.);
Section of Abdominal Imaging, Imaging Institute, Digestive Diseases and Surgery
Institute and Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio
(M.E.B.); Department of Radiology, University of California San Diego, San
Diego, Calif (C.S.S.); Department of Radiology, IBD Unit, Hospital Clínic
de Barcelona, Barcelona, Spain (N.C., J. Rimola); Pediatric and Adult
Cardiothoracic and Vascular, Oncohematologic and Emergency Radiology Unit, IRCCS
Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy (N.C.); Centre for
Medical Imaging, University College London, London, England (S.A.T.); Division
of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science,
Rochester, Minn (D.H.B.); and Departments of Medicine and Epidemiology and
Biostatistics, Schulich School of Medicine and Dentistry, University of Western
Ontario, London, Ontario, Canada (B.G.F., V.J.)
| | - Guangyong Zou
- From the Department of Inflammation and Immunity, Lerner Research
Institute, Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH 44195 (F.R.);
Department of Gastroenterology, Hepatology, and Nutrition, Digestive Diseases
and Surgery Institute and Program for Global Translational Inflammatory Bowel
Diseases Research, Cleveland Clinic, Cleveland, Ohio (F.R., M.P., J.N., R.O.);
Departments of Medicine and Community Health Sciences, Division of
Gastroenterology and Hepatology, University of Calgary, Calgary, Alberta, Canada
(C.M.); Alimentiv, London, Ontario, Canada (C.M., J.H., Z.W., L.G., L.M.S., J.
Rémillard, G.Z., B.G.F., V.J.); Department of Gastroenterology,
University of Ljubljana, University Medical Centre Ljubljana, Ljubljana,
Slovenia (J.H.); Department of Radiology, Mayo Clinic, Rochester, Minn (J.G.F.);
Section of Abdominal Imaging, Imaging Institute, Digestive Diseases and Surgery
Institute and Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio
(M.E.B.); Department of Radiology, University of California San Diego, San
Diego, Calif (C.S.S.); Department of Radiology, IBD Unit, Hospital Clínic
de Barcelona, Barcelona, Spain (N.C., J. Rimola); Pediatric and Adult
Cardiothoracic and Vascular, Oncohematologic and Emergency Radiology Unit, IRCCS
Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy (N.C.); Centre for
Medical Imaging, University College London, London, England (S.A.T.); Division
of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science,
Rochester, Minn (D.H.B.); and Departments of Medicine and Epidemiology and
Biostatistics, Schulich School of Medicine and Dentistry, University of Western
Ontario, London, Ontario, Canada (B.G.F., V.J.)
| | - Brian G. Feagan
- From the Department of Inflammation and Immunity, Lerner Research
Institute, Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH 44195 (F.R.);
Department of Gastroenterology, Hepatology, and Nutrition, Digestive Diseases
and Surgery Institute and Program for Global Translational Inflammatory Bowel
Diseases Research, Cleveland Clinic, Cleveland, Ohio (F.R., M.P., J.N., R.O.);
Departments of Medicine and Community Health Sciences, Division of
Gastroenterology and Hepatology, University of Calgary, Calgary, Alberta, Canada
(C.M.); Alimentiv, London, Ontario, Canada (C.M., J.H., Z.W., L.G., L.M.S., J.
Rémillard, G.Z., B.G.F., V.J.); Department of Gastroenterology,
University of Ljubljana, University Medical Centre Ljubljana, Ljubljana,
Slovenia (J.H.); Department of Radiology, Mayo Clinic, Rochester, Minn (J.G.F.);
Section of Abdominal Imaging, Imaging Institute, Digestive Diseases and Surgery
Institute and Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio
(M.E.B.); Department of Radiology, University of California San Diego, San
Diego, Calif (C.S.S.); Department of Radiology, IBD Unit, Hospital Clínic
de Barcelona, Barcelona, Spain (N.C., J. Rimola); Pediatric and Adult
Cardiothoracic and Vascular, Oncohematologic and Emergency Radiology Unit, IRCCS
Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy (N.C.); Centre for
Medical Imaging, University College London, London, England (S.A.T.); Division
of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science,
Rochester, Minn (D.H.B.); and Departments of Medicine and Epidemiology and
Biostatistics, Schulich School of Medicine and Dentistry, University of Western
Ontario, London, Ontario, Canada (B.G.F., V.J.)
| | | | | | - for the Stenosis Therapy and Anti-Fibrotic Research (STAR)
Consortium
- From the Department of Inflammation and Immunity, Lerner Research
Institute, Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH 44195 (F.R.);
Department of Gastroenterology, Hepatology, and Nutrition, Digestive Diseases
and Surgery Institute and Program for Global Translational Inflammatory Bowel
Diseases Research, Cleveland Clinic, Cleveland, Ohio (F.R., M.P., J.N., R.O.);
Departments of Medicine and Community Health Sciences, Division of
Gastroenterology and Hepatology, University of Calgary, Calgary, Alberta, Canada
(C.M.); Alimentiv, London, Ontario, Canada (C.M., J.H., Z.W., L.G., L.M.S., J.
Rémillard, G.Z., B.G.F., V.J.); Department of Gastroenterology,
University of Ljubljana, University Medical Centre Ljubljana, Ljubljana,
Slovenia (J.H.); Department of Radiology, Mayo Clinic, Rochester, Minn (J.G.F.);
Section of Abdominal Imaging, Imaging Institute, Digestive Diseases and Surgery
Institute and Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio
(M.E.B.); Department of Radiology, University of California San Diego, San
Diego, Calif (C.S.S.); Department of Radiology, IBD Unit, Hospital Clínic
de Barcelona, Barcelona, Spain (N.C., J. Rimola); Pediatric and Adult
Cardiothoracic and Vascular, Oncohematologic and Emergency Radiology Unit, IRCCS
Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy (N.C.); Centre for
Medical Imaging, University College London, London, England (S.A.T.); Division
of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science,
Rochester, Minn (D.H.B.); and Departments of Medicine and Epidemiology and
Biostatistics, Schulich School of Medicine and Dentistry, University of Western
Ontario, London, Ontario, Canada (B.G.F., V.J.)
| | - Sarah Atzen
- From the Department of Inflammation and Immunity, Lerner Research
Institute, Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH 44195 (F.R.);
Department of Gastroenterology, Hepatology, and Nutrition, Digestive Diseases
and Surgery Institute and Program for Global Translational Inflammatory Bowel
Diseases Research, Cleveland Clinic, Cleveland, Ohio (F.R., M.P., J.N., R.O.);
Departments of Medicine and Community Health Sciences, Division of
Gastroenterology and Hepatology, University of Calgary, Calgary, Alberta, Canada
(C.M.); Alimentiv, London, Ontario, Canada (C.M., J.H., Z.W., L.G., L.M.S., J.
Rémillard, G.Z., B.G.F., V.J.); Department of Gastroenterology,
University of Ljubljana, University Medical Centre Ljubljana, Ljubljana,
Slovenia (J.H.); Department of Radiology, Mayo Clinic, Rochester, Minn (J.G.F.);
Section of Abdominal Imaging, Imaging Institute, Digestive Diseases and Surgery
Institute and Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio
(M.E.B.); Department of Radiology, University of California San Diego, San
Diego, Calif (C.S.S.); Department of Radiology, IBD Unit, Hospital Clínic
de Barcelona, Barcelona, Spain (N.C., J. Rimola); Pediatric and Adult
Cardiothoracic and Vascular, Oncohematologic and Emergency Radiology Unit, IRCCS
Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy (N.C.); Centre for
Medical Imaging, University College London, London, England (S.A.T.); Division
of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science,
Rochester, Minn (D.H.B.); and Departments of Medicine and Epidemiology and
Biostatistics, Schulich School of Medicine and Dentistry, University of Western
Ontario, London, Ontario, Canada (B.G.F., V.J.)
| |
Collapse
|
11
|
Rieder F, Baker ME, Bruining DH, Fidler JL, Ehman EC, Sheedy SP, Heiken JP, Ream JM, Holmes DR, Inoue A, Mohammadinejad P, Lee YS, Taylor SA, Stoker J, Zou G, Wang Z, Rémillard J, Carter RE, Ottichilo R, Atkinson N, Siddiqui MT, Sunkesula VC, Ma C, Parker CE, Panés J, Rimola J, Jairath V, Feagan BG, Fletcher JG, Atzen S. Reliability of MR Enterography Features for Describing Fibrostenosing Crohn Disease. Radiology 2024; 312:e233039. [PMID: 39105637 PMCID: PMC11366673 DOI: 10.1148/radiol.233039] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2023] [Revised: 04/12/2024] [Accepted: 04/23/2024] [Indexed: 08/07/2024]
Abstract
Background Clinical decision making and drug development for fibrostenosing Crohn disease is constrained by a lack of imaging definitions, scoring conventions, and validated end points. Purpose To assess the reliability of MR enterography features to describe Crohn disease strictures and determine correlation with stricture severity. Materials and Methods A retrospective study of patients with symptomatic terminal ileal Crohn disease strictures who underwent MR enterography at tertiary care centers (Cleveland Clinic: September 2013 to November 2020; Mayo Clinic: February 2008 to March 2019) was conducted by using convenience sampling. In the development phase, blinded and trained radiologists independently evaluated 26 MR enterography features from baseline and follow-up examinations performed more than 6 months apart, with no bowel resection performed between examinations. Follow-up examinations closest to 12 months after baseline were selected. Reliability was assessed using the intraclass correlation coefficient (ICC). In the validation phase, after five features were redefined, reliability was re-estimated in an independent convenience sample using baseline examinations. Multivariable linear regression analysis identified features with at least moderate interrater reliability (ICC ≥0.41) that were independently associated with stricture severity. Results Ninety-nine (mean age, 40 years ± 14 [SD]; 50 male) patients were included in the development group and 51 (mean age, 45 years ± 16 [SD]; 35 female) patients were included in the validation group. In the development group, nine features had at least moderate interrater reliability. One additional feature demonstrated moderate reliability in the validation group. Stricture length (ICC = 0.85 [95% CI: 0.75, 0.91] and 0.91 [95% CI: 0.75, 0.96] in development and validation phase, respectively) and maximal associated small bowel dilation (ICC = 0.74 [95% CI: 0.63, 0.80] and 0.73 [95% CI: 0.58, 0.87] in development and validation group, respectively) had the highest interrater reliability. Stricture length, maximal stricture wall thickness, and maximal associated small bowel dilation were independently (regression coefficients, 0.09-3.97; P < .001) associated with stricture severity. Conclusion MR enterography definitions and scoring conventions for reliably assessing features of Crohn disease strictures were developed and validated, and feature correlation with stricture severity was determined. © RSNA, 2024 Supplemental material is available for this article. See also the article by Rieder and Ma et al in this issue. See also the editorial by Galgano and Summerlin in this issue.
Collapse
Affiliation(s)
- Florian Rieder
- From the Department of Inflammation and Immunity, Lerner Research
Institute (F.R., R.O., N.A.), Department of Gastroenterology, Hepatology and
Nutrition, Digestive Diseases (F.R., M.T.S., V.C.S.), and Program for Global
Translational Inflammatory Bowel Disease Research (F.R., R.O.), Cleveland Clinic
Foundation, Cleveland, Ohio; Section of Abdominal Imaging, Imaging, Digestive
Diseases and Surgery and Cancer Institutes (M.E.B.) and Department of Diagnostic
Radiology (J.M.R.) Cleveland Clinic Foundation, Cleveland, Ohio; Division of
Gastroenterology and Hepatology (D.H.B.), Biomedical Imaging Resource (D.R.H.),
and Department of Radiology (J.L.F., E.C.E., S.P.S., J.P.H., D.R.H., Y.S.L.,
J.G.F.), Mayo Clinic, 200 First St, Rochester, MN 55905; Department of
Radiology, Shiga University of Medical Science, Shiga, Japan (A.I.); Department
of Radiology, University of Texas Medical Branch, Galveston, Tex (P.M.); Centre
for Medical Imaging, University College London, London, United Kingdom (S.A.T.);
Department of Radiology and Nuclear Medicine, Amsterdam University Medical
Centre, University of Amsterdam, Amsterdam, the Netherlands (J.S.); Alimentiv,
London, Ontario, Canada (G.Z., Z.W., J. Rémillard, C.M., C.E.P., V.J.,
B.G.F.); Department of Epidemiology and Biostatistics, Western University,
London, Ontario, Canada (G.Z., V.J., B.G.F.); Department of Quantitative Health
Sciences, Mayo Clinic, Jacksonville, Fla (R.E.C.); Division of Gastroenterology
and Hepatology, University of Calgary, Calgary, Alberta, Canada (C.M.);
Departments of Gastroenterology (J.P.) and Radiology (J. Rimola), Hospital
Clínic de Barcelona, Barcelona, Spain; and Department of Medicine,
Division of Gastroenterology, Western University, London, Ontario, Canada (V.J.,
B.G.F.)
| | - Mark E. Baker
- From the Department of Inflammation and Immunity, Lerner Research
Institute (F.R., R.O., N.A.), Department of Gastroenterology, Hepatology and
Nutrition, Digestive Diseases (F.R., M.T.S., V.C.S.), and Program for Global
Translational Inflammatory Bowel Disease Research (F.R., R.O.), Cleveland Clinic
Foundation, Cleveland, Ohio; Section of Abdominal Imaging, Imaging, Digestive
Diseases and Surgery and Cancer Institutes (M.E.B.) and Department of Diagnostic
Radiology (J.M.R.) Cleveland Clinic Foundation, Cleveland, Ohio; Division of
Gastroenterology and Hepatology (D.H.B.), Biomedical Imaging Resource (D.R.H.),
and Department of Radiology (J.L.F., E.C.E., S.P.S., J.P.H., D.R.H., Y.S.L.,
J.G.F.), Mayo Clinic, 200 First St, Rochester, MN 55905; Department of
Radiology, Shiga University of Medical Science, Shiga, Japan (A.I.); Department
of Radiology, University of Texas Medical Branch, Galveston, Tex (P.M.); Centre
for Medical Imaging, University College London, London, United Kingdom (S.A.T.);
Department of Radiology and Nuclear Medicine, Amsterdam University Medical
Centre, University of Amsterdam, Amsterdam, the Netherlands (J.S.); Alimentiv,
London, Ontario, Canada (G.Z., Z.W., J. Rémillard, C.M., C.E.P., V.J.,
B.G.F.); Department of Epidemiology and Biostatistics, Western University,
London, Ontario, Canada (G.Z., V.J., B.G.F.); Department of Quantitative Health
Sciences, Mayo Clinic, Jacksonville, Fla (R.E.C.); Division of Gastroenterology
and Hepatology, University of Calgary, Calgary, Alberta, Canada (C.M.);
Departments of Gastroenterology (J.P.) and Radiology (J. Rimola), Hospital
Clínic de Barcelona, Barcelona, Spain; and Department of Medicine,
Division of Gastroenterology, Western University, London, Ontario, Canada (V.J.,
B.G.F.)
| | - David H. Bruining
- From the Department of Inflammation and Immunity, Lerner Research
Institute (F.R., R.O., N.A.), Department of Gastroenterology, Hepatology and
Nutrition, Digestive Diseases (F.R., M.T.S., V.C.S.), and Program for Global
Translational Inflammatory Bowel Disease Research (F.R., R.O.), Cleveland Clinic
Foundation, Cleveland, Ohio; Section of Abdominal Imaging, Imaging, Digestive
Diseases and Surgery and Cancer Institutes (M.E.B.) and Department of Diagnostic
Radiology (J.M.R.) Cleveland Clinic Foundation, Cleveland, Ohio; Division of
Gastroenterology and Hepatology (D.H.B.), Biomedical Imaging Resource (D.R.H.),
and Department of Radiology (J.L.F., E.C.E., S.P.S., J.P.H., D.R.H., Y.S.L.,
J.G.F.), Mayo Clinic, 200 First St, Rochester, MN 55905; Department of
Radiology, Shiga University of Medical Science, Shiga, Japan (A.I.); Department
of Radiology, University of Texas Medical Branch, Galveston, Tex (P.M.); Centre
for Medical Imaging, University College London, London, United Kingdom (S.A.T.);
Department of Radiology and Nuclear Medicine, Amsterdam University Medical
Centre, University of Amsterdam, Amsterdam, the Netherlands (J.S.); Alimentiv,
London, Ontario, Canada (G.Z., Z.W., J. Rémillard, C.M., C.E.P., V.J.,
B.G.F.); Department of Epidemiology and Biostatistics, Western University,
London, Ontario, Canada (G.Z., V.J., B.G.F.); Department of Quantitative Health
Sciences, Mayo Clinic, Jacksonville, Fla (R.E.C.); Division of Gastroenterology
and Hepatology, University of Calgary, Calgary, Alberta, Canada (C.M.);
Departments of Gastroenterology (J.P.) and Radiology (J. Rimola), Hospital
Clínic de Barcelona, Barcelona, Spain; and Department of Medicine,
Division of Gastroenterology, Western University, London, Ontario, Canada (V.J.,
B.G.F.)
| | - Jeff L. Fidler
- From the Department of Inflammation and Immunity, Lerner Research
Institute (F.R., R.O., N.A.), Department of Gastroenterology, Hepatology and
Nutrition, Digestive Diseases (F.R., M.T.S., V.C.S.), and Program for Global
Translational Inflammatory Bowel Disease Research (F.R., R.O.), Cleveland Clinic
Foundation, Cleveland, Ohio; Section of Abdominal Imaging, Imaging, Digestive
Diseases and Surgery and Cancer Institutes (M.E.B.) and Department of Diagnostic
Radiology (J.M.R.) Cleveland Clinic Foundation, Cleveland, Ohio; Division of
Gastroenterology and Hepatology (D.H.B.), Biomedical Imaging Resource (D.R.H.),
and Department of Radiology (J.L.F., E.C.E., S.P.S., J.P.H., D.R.H., Y.S.L.,
J.G.F.), Mayo Clinic, 200 First St, Rochester, MN 55905; Department of
Radiology, Shiga University of Medical Science, Shiga, Japan (A.I.); Department
of Radiology, University of Texas Medical Branch, Galveston, Tex (P.M.); Centre
for Medical Imaging, University College London, London, United Kingdom (S.A.T.);
Department of Radiology and Nuclear Medicine, Amsterdam University Medical
Centre, University of Amsterdam, Amsterdam, the Netherlands (J.S.); Alimentiv,
London, Ontario, Canada (G.Z., Z.W., J. Rémillard, C.M., C.E.P., V.J.,
B.G.F.); Department of Epidemiology and Biostatistics, Western University,
London, Ontario, Canada (G.Z., V.J., B.G.F.); Department of Quantitative Health
Sciences, Mayo Clinic, Jacksonville, Fla (R.E.C.); Division of Gastroenterology
and Hepatology, University of Calgary, Calgary, Alberta, Canada (C.M.);
Departments of Gastroenterology (J.P.) and Radiology (J. Rimola), Hospital
Clínic de Barcelona, Barcelona, Spain; and Department of Medicine,
Division of Gastroenterology, Western University, London, Ontario, Canada (V.J.,
B.G.F.)
| | - Eric C. Ehman
- From the Department of Inflammation and Immunity, Lerner Research
Institute (F.R., R.O., N.A.), Department of Gastroenterology, Hepatology and
Nutrition, Digestive Diseases (F.R., M.T.S., V.C.S.), and Program for Global
Translational Inflammatory Bowel Disease Research (F.R., R.O.), Cleveland Clinic
Foundation, Cleveland, Ohio; Section of Abdominal Imaging, Imaging, Digestive
Diseases and Surgery and Cancer Institutes (M.E.B.) and Department of Diagnostic
Radiology (J.M.R.) Cleveland Clinic Foundation, Cleveland, Ohio; Division of
Gastroenterology and Hepatology (D.H.B.), Biomedical Imaging Resource (D.R.H.),
and Department of Radiology (J.L.F., E.C.E., S.P.S., J.P.H., D.R.H., Y.S.L.,
J.G.F.), Mayo Clinic, 200 First St, Rochester, MN 55905; Department of
Radiology, Shiga University of Medical Science, Shiga, Japan (A.I.); Department
of Radiology, University of Texas Medical Branch, Galveston, Tex (P.M.); Centre
for Medical Imaging, University College London, London, United Kingdom (S.A.T.);
Department of Radiology and Nuclear Medicine, Amsterdam University Medical
Centre, University of Amsterdam, Amsterdam, the Netherlands (J.S.); Alimentiv,
London, Ontario, Canada (G.Z., Z.W., J. Rémillard, C.M., C.E.P., V.J.,
B.G.F.); Department of Epidemiology and Biostatistics, Western University,
London, Ontario, Canada (G.Z., V.J., B.G.F.); Department of Quantitative Health
Sciences, Mayo Clinic, Jacksonville, Fla (R.E.C.); Division of Gastroenterology
and Hepatology, University of Calgary, Calgary, Alberta, Canada (C.M.);
Departments of Gastroenterology (J.P.) and Radiology (J. Rimola), Hospital
Clínic de Barcelona, Barcelona, Spain; and Department of Medicine,
Division of Gastroenterology, Western University, London, Ontario, Canada (V.J.,
B.G.F.)
| | - Shannon P. Sheedy
- From the Department of Inflammation and Immunity, Lerner Research
Institute (F.R., R.O., N.A.), Department of Gastroenterology, Hepatology and
Nutrition, Digestive Diseases (F.R., M.T.S., V.C.S.), and Program for Global
Translational Inflammatory Bowel Disease Research (F.R., R.O.), Cleveland Clinic
Foundation, Cleveland, Ohio; Section of Abdominal Imaging, Imaging, Digestive
Diseases and Surgery and Cancer Institutes (M.E.B.) and Department of Diagnostic
Radiology (J.M.R.) Cleveland Clinic Foundation, Cleveland, Ohio; Division of
Gastroenterology and Hepatology (D.H.B.), Biomedical Imaging Resource (D.R.H.),
and Department of Radiology (J.L.F., E.C.E., S.P.S., J.P.H., D.R.H., Y.S.L.,
J.G.F.), Mayo Clinic, 200 First St, Rochester, MN 55905; Department of
Radiology, Shiga University of Medical Science, Shiga, Japan (A.I.); Department
of Radiology, University of Texas Medical Branch, Galveston, Tex (P.M.); Centre
for Medical Imaging, University College London, London, United Kingdom (S.A.T.);
Department of Radiology and Nuclear Medicine, Amsterdam University Medical
Centre, University of Amsterdam, Amsterdam, the Netherlands (J.S.); Alimentiv,
London, Ontario, Canada (G.Z., Z.W., J. Rémillard, C.M., C.E.P., V.J.,
B.G.F.); Department of Epidemiology and Biostatistics, Western University,
London, Ontario, Canada (G.Z., V.J., B.G.F.); Department of Quantitative Health
Sciences, Mayo Clinic, Jacksonville, Fla (R.E.C.); Division of Gastroenterology
and Hepatology, University of Calgary, Calgary, Alberta, Canada (C.M.);
Departments of Gastroenterology (J.P.) and Radiology (J. Rimola), Hospital
Clínic de Barcelona, Barcelona, Spain; and Department of Medicine,
Division of Gastroenterology, Western University, London, Ontario, Canada (V.J.,
B.G.F.)
| | - Jay P. Heiken
- From the Department of Inflammation and Immunity, Lerner Research
Institute (F.R., R.O., N.A.), Department of Gastroenterology, Hepatology and
Nutrition, Digestive Diseases (F.R., M.T.S., V.C.S.), and Program for Global
Translational Inflammatory Bowel Disease Research (F.R., R.O.), Cleveland Clinic
Foundation, Cleveland, Ohio; Section of Abdominal Imaging, Imaging, Digestive
Diseases and Surgery and Cancer Institutes (M.E.B.) and Department of Diagnostic
Radiology (J.M.R.) Cleveland Clinic Foundation, Cleveland, Ohio; Division of
Gastroenterology and Hepatology (D.H.B.), Biomedical Imaging Resource (D.R.H.),
and Department of Radiology (J.L.F., E.C.E., S.P.S., J.P.H., D.R.H., Y.S.L.,
J.G.F.), Mayo Clinic, 200 First St, Rochester, MN 55905; Department of
Radiology, Shiga University of Medical Science, Shiga, Japan (A.I.); Department
of Radiology, University of Texas Medical Branch, Galveston, Tex (P.M.); Centre
for Medical Imaging, University College London, London, United Kingdom (S.A.T.);
Department of Radiology and Nuclear Medicine, Amsterdam University Medical
Centre, University of Amsterdam, Amsterdam, the Netherlands (J.S.); Alimentiv,
London, Ontario, Canada (G.Z., Z.W., J. Rémillard, C.M., C.E.P., V.J.,
B.G.F.); Department of Epidemiology and Biostatistics, Western University,
London, Ontario, Canada (G.Z., V.J., B.G.F.); Department of Quantitative Health
Sciences, Mayo Clinic, Jacksonville, Fla (R.E.C.); Division of Gastroenterology
and Hepatology, University of Calgary, Calgary, Alberta, Canada (C.M.);
Departments of Gastroenterology (J.P.) and Radiology (J. Rimola), Hospital
Clínic de Barcelona, Barcelona, Spain; and Department of Medicine,
Division of Gastroenterology, Western University, London, Ontario, Canada (V.J.,
B.G.F.)
| | - Justin M. Ream
- From the Department of Inflammation and Immunity, Lerner Research
Institute (F.R., R.O., N.A.), Department of Gastroenterology, Hepatology and
Nutrition, Digestive Diseases (F.R., M.T.S., V.C.S.), and Program for Global
Translational Inflammatory Bowel Disease Research (F.R., R.O.), Cleveland Clinic
Foundation, Cleveland, Ohio; Section of Abdominal Imaging, Imaging, Digestive
Diseases and Surgery and Cancer Institutes (M.E.B.) and Department of Diagnostic
Radiology (J.M.R.) Cleveland Clinic Foundation, Cleveland, Ohio; Division of
Gastroenterology and Hepatology (D.H.B.), Biomedical Imaging Resource (D.R.H.),
and Department of Radiology (J.L.F., E.C.E., S.P.S., J.P.H., D.R.H., Y.S.L.,
J.G.F.), Mayo Clinic, 200 First St, Rochester, MN 55905; Department of
Radiology, Shiga University of Medical Science, Shiga, Japan (A.I.); Department
of Radiology, University of Texas Medical Branch, Galveston, Tex (P.M.); Centre
for Medical Imaging, University College London, London, United Kingdom (S.A.T.);
Department of Radiology and Nuclear Medicine, Amsterdam University Medical
Centre, University of Amsterdam, Amsterdam, the Netherlands (J.S.); Alimentiv,
London, Ontario, Canada (G.Z., Z.W., J. Rémillard, C.M., C.E.P., V.J.,
B.G.F.); Department of Epidemiology and Biostatistics, Western University,
London, Ontario, Canada (G.Z., V.J., B.G.F.); Department of Quantitative Health
Sciences, Mayo Clinic, Jacksonville, Fla (R.E.C.); Division of Gastroenterology
and Hepatology, University of Calgary, Calgary, Alberta, Canada (C.M.);
Departments of Gastroenterology (J.P.) and Radiology (J. Rimola), Hospital
Clínic de Barcelona, Barcelona, Spain; and Department of Medicine,
Division of Gastroenterology, Western University, London, Ontario, Canada (V.J.,
B.G.F.)
| | - David R. Holmes
- From the Department of Inflammation and Immunity, Lerner Research
Institute (F.R., R.O., N.A.), Department of Gastroenterology, Hepatology and
Nutrition, Digestive Diseases (F.R., M.T.S., V.C.S.), and Program for Global
Translational Inflammatory Bowel Disease Research (F.R., R.O.), Cleveland Clinic
Foundation, Cleveland, Ohio; Section of Abdominal Imaging, Imaging, Digestive
Diseases and Surgery and Cancer Institutes (M.E.B.) and Department of Diagnostic
Radiology (J.M.R.) Cleveland Clinic Foundation, Cleveland, Ohio; Division of
Gastroenterology and Hepatology (D.H.B.), Biomedical Imaging Resource (D.R.H.),
and Department of Radiology (J.L.F., E.C.E., S.P.S., J.P.H., D.R.H., Y.S.L.,
J.G.F.), Mayo Clinic, 200 First St, Rochester, MN 55905; Department of
Radiology, Shiga University of Medical Science, Shiga, Japan (A.I.); Department
of Radiology, University of Texas Medical Branch, Galveston, Tex (P.M.); Centre
for Medical Imaging, University College London, London, United Kingdom (S.A.T.);
Department of Radiology and Nuclear Medicine, Amsterdam University Medical
Centre, University of Amsterdam, Amsterdam, the Netherlands (J.S.); Alimentiv,
London, Ontario, Canada (G.Z., Z.W., J. Rémillard, C.M., C.E.P., V.J.,
B.G.F.); Department of Epidemiology and Biostatistics, Western University,
London, Ontario, Canada (G.Z., V.J., B.G.F.); Department of Quantitative Health
Sciences, Mayo Clinic, Jacksonville, Fla (R.E.C.); Division of Gastroenterology
and Hepatology, University of Calgary, Calgary, Alberta, Canada (C.M.);
Departments of Gastroenterology (J.P.) and Radiology (J. Rimola), Hospital
Clínic de Barcelona, Barcelona, Spain; and Department of Medicine,
Division of Gastroenterology, Western University, London, Ontario, Canada (V.J.,
B.G.F.)
| | - Akitoshi Inoue
- From the Department of Inflammation and Immunity, Lerner Research
Institute (F.R., R.O., N.A.), Department of Gastroenterology, Hepatology and
Nutrition, Digestive Diseases (F.R., M.T.S., V.C.S.), and Program for Global
Translational Inflammatory Bowel Disease Research (F.R., R.O.), Cleveland Clinic
Foundation, Cleveland, Ohio; Section of Abdominal Imaging, Imaging, Digestive
Diseases and Surgery and Cancer Institutes (M.E.B.) and Department of Diagnostic
Radiology (J.M.R.) Cleveland Clinic Foundation, Cleveland, Ohio; Division of
Gastroenterology and Hepatology (D.H.B.), Biomedical Imaging Resource (D.R.H.),
and Department of Radiology (J.L.F., E.C.E., S.P.S., J.P.H., D.R.H., Y.S.L.,
J.G.F.), Mayo Clinic, 200 First St, Rochester, MN 55905; Department of
Radiology, Shiga University of Medical Science, Shiga, Japan (A.I.); Department
of Radiology, University of Texas Medical Branch, Galveston, Tex (P.M.); Centre
for Medical Imaging, University College London, London, United Kingdom (S.A.T.);
Department of Radiology and Nuclear Medicine, Amsterdam University Medical
Centre, University of Amsterdam, Amsterdam, the Netherlands (J.S.); Alimentiv,
London, Ontario, Canada (G.Z., Z.W., J. Rémillard, C.M., C.E.P., V.J.,
B.G.F.); Department of Epidemiology and Biostatistics, Western University,
London, Ontario, Canada (G.Z., V.J., B.G.F.); Department of Quantitative Health
Sciences, Mayo Clinic, Jacksonville, Fla (R.E.C.); Division of Gastroenterology
and Hepatology, University of Calgary, Calgary, Alberta, Canada (C.M.);
Departments of Gastroenterology (J.P.) and Radiology (J. Rimola), Hospital
Clínic de Barcelona, Barcelona, Spain; and Department of Medicine,
Division of Gastroenterology, Western University, London, Ontario, Canada (V.J.,
B.G.F.)
| | - Payam Mohammadinejad
- From the Department of Inflammation and Immunity, Lerner Research
Institute (F.R., R.O., N.A.), Department of Gastroenterology, Hepatology and
Nutrition, Digestive Diseases (F.R., M.T.S., V.C.S.), and Program for Global
Translational Inflammatory Bowel Disease Research (F.R., R.O.), Cleveland Clinic
Foundation, Cleveland, Ohio; Section of Abdominal Imaging, Imaging, Digestive
Diseases and Surgery and Cancer Institutes (M.E.B.) and Department of Diagnostic
Radiology (J.M.R.) Cleveland Clinic Foundation, Cleveland, Ohio; Division of
Gastroenterology and Hepatology (D.H.B.), Biomedical Imaging Resource (D.R.H.),
and Department of Radiology (J.L.F., E.C.E., S.P.S., J.P.H., D.R.H., Y.S.L.,
J.G.F.), Mayo Clinic, 200 First St, Rochester, MN 55905; Department of
Radiology, Shiga University of Medical Science, Shiga, Japan (A.I.); Department
of Radiology, University of Texas Medical Branch, Galveston, Tex (P.M.); Centre
for Medical Imaging, University College London, London, United Kingdom (S.A.T.);
Department of Radiology and Nuclear Medicine, Amsterdam University Medical
Centre, University of Amsterdam, Amsterdam, the Netherlands (J.S.); Alimentiv,
London, Ontario, Canada (G.Z., Z.W., J. Rémillard, C.M., C.E.P., V.J.,
B.G.F.); Department of Epidemiology and Biostatistics, Western University,
London, Ontario, Canada (G.Z., V.J., B.G.F.); Department of Quantitative Health
Sciences, Mayo Clinic, Jacksonville, Fla (R.E.C.); Division of Gastroenterology
and Hepatology, University of Calgary, Calgary, Alberta, Canada (C.M.);
Departments of Gastroenterology (J.P.) and Radiology (J. Rimola), Hospital
Clínic de Barcelona, Barcelona, Spain; and Department of Medicine,
Division of Gastroenterology, Western University, London, Ontario, Canada (V.J.,
B.G.F.)
| | - Yong S. Lee
- From the Department of Inflammation and Immunity, Lerner Research
Institute (F.R., R.O., N.A.), Department of Gastroenterology, Hepatology and
Nutrition, Digestive Diseases (F.R., M.T.S., V.C.S.), and Program for Global
Translational Inflammatory Bowel Disease Research (F.R., R.O.), Cleveland Clinic
Foundation, Cleveland, Ohio; Section of Abdominal Imaging, Imaging, Digestive
Diseases and Surgery and Cancer Institutes (M.E.B.) and Department of Diagnostic
Radiology (J.M.R.) Cleveland Clinic Foundation, Cleveland, Ohio; Division of
Gastroenterology and Hepatology (D.H.B.), Biomedical Imaging Resource (D.R.H.),
and Department of Radiology (J.L.F., E.C.E., S.P.S., J.P.H., D.R.H., Y.S.L.,
J.G.F.), Mayo Clinic, 200 First St, Rochester, MN 55905; Department of
Radiology, Shiga University of Medical Science, Shiga, Japan (A.I.); Department
of Radiology, University of Texas Medical Branch, Galveston, Tex (P.M.); Centre
for Medical Imaging, University College London, London, United Kingdom (S.A.T.);
Department of Radiology and Nuclear Medicine, Amsterdam University Medical
Centre, University of Amsterdam, Amsterdam, the Netherlands (J.S.); Alimentiv,
London, Ontario, Canada (G.Z., Z.W., J. Rémillard, C.M., C.E.P., V.J.,
B.G.F.); Department of Epidemiology and Biostatistics, Western University,
London, Ontario, Canada (G.Z., V.J., B.G.F.); Department of Quantitative Health
Sciences, Mayo Clinic, Jacksonville, Fla (R.E.C.); Division of Gastroenterology
and Hepatology, University of Calgary, Calgary, Alberta, Canada (C.M.);
Departments of Gastroenterology (J.P.) and Radiology (J. Rimola), Hospital
Clínic de Barcelona, Barcelona, Spain; and Department of Medicine,
Division of Gastroenterology, Western University, London, Ontario, Canada (V.J.,
B.G.F.)
| | - Stuart A. Taylor
- From the Department of Inflammation and Immunity, Lerner Research
Institute (F.R., R.O., N.A.), Department of Gastroenterology, Hepatology and
Nutrition, Digestive Diseases (F.R., M.T.S., V.C.S.), and Program for Global
Translational Inflammatory Bowel Disease Research (F.R., R.O.), Cleveland Clinic
Foundation, Cleveland, Ohio; Section of Abdominal Imaging, Imaging, Digestive
Diseases and Surgery and Cancer Institutes (M.E.B.) and Department of Diagnostic
Radiology (J.M.R.) Cleveland Clinic Foundation, Cleveland, Ohio; Division of
Gastroenterology and Hepatology (D.H.B.), Biomedical Imaging Resource (D.R.H.),
and Department of Radiology (J.L.F., E.C.E., S.P.S., J.P.H., D.R.H., Y.S.L.,
J.G.F.), Mayo Clinic, 200 First St, Rochester, MN 55905; Department of
Radiology, Shiga University of Medical Science, Shiga, Japan (A.I.); Department
of Radiology, University of Texas Medical Branch, Galveston, Tex (P.M.); Centre
for Medical Imaging, University College London, London, United Kingdom (S.A.T.);
Department of Radiology and Nuclear Medicine, Amsterdam University Medical
Centre, University of Amsterdam, Amsterdam, the Netherlands (J.S.); Alimentiv,
London, Ontario, Canada (G.Z., Z.W., J. Rémillard, C.M., C.E.P., V.J.,
B.G.F.); Department of Epidemiology and Biostatistics, Western University,
London, Ontario, Canada (G.Z., V.J., B.G.F.); Department of Quantitative Health
Sciences, Mayo Clinic, Jacksonville, Fla (R.E.C.); Division of Gastroenterology
and Hepatology, University of Calgary, Calgary, Alberta, Canada (C.M.);
Departments of Gastroenterology (J.P.) and Radiology (J. Rimola), Hospital
Clínic de Barcelona, Barcelona, Spain; and Department of Medicine,
Division of Gastroenterology, Western University, London, Ontario, Canada (V.J.,
B.G.F.)
| | - Jaap Stoker
- From the Department of Inflammation and Immunity, Lerner Research
Institute (F.R., R.O., N.A.), Department of Gastroenterology, Hepatology and
Nutrition, Digestive Diseases (F.R., M.T.S., V.C.S.), and Program for Global
Translational Inflammatory Bowel Disease Research (F.R., R.O.), Cleveland Clinic
Foundation, Cleveland, Ohio; Section of Abdominal Imaging, Imaging, Digestive
Diseases and Surgery and Cancer Institutes (M.E.B.) and Department of Diagnostic
Radiology (J.M.R.) Cleveland Clinic Foundation, Cleveland, Ohio; Division of
Gastroenterology and Hepatology (D.H.B.), Biomedical Imaging Resource (D.R.H.),
and Department of Radiology (J.L.F., E.C.E., S.P.S., J.P.H., D.R.H., Y.S.L.,
J.G.F.), Mayo Clinic, 200 First St, Rochester, MN 55905; Department of
Radiology, Shiga University of Medical Science, Shiga, Japan (A.I.); Department
of Radiology, University of Texas Medical Branch, Galveston, Tex (P.M.); Centre
for Medical Imaging, University College London, London, United Kingdom (S.A.T.);
Department of Radiology and Nuclear Medicine, Amsterdam University Medical
Centre, University of Amsterdam, Amsterdam, the Netherlands (J.S.); Alimentiv,
London, Ontario, Canada (G.Z., Z.W., J. Rémillard, C.M., C.E.P., V.J.,
B.G.F.); Department of Epidemiology and Biostatistics, Western University,
London, Ontario, Canada (G.Z., V.J., B.G.F.); Department of Quantitative Health
Sciences, Mayo Clinic, Jacksonville, Fla (R.E.C.); Division of Gastroenterology
and Hepatology, University of Calgary, Calgary, Alberta, Canada (C.M.);
Departments of Gastroenterology (J.P.) and Radiology (J. Rimola), Hospital
Clínic de Barcelona, Barcelona, Spain; and Department of Medicine,
Division of Gastroenterology, Western University, London, Ontario, Canada (V.J.,
B.G.F.)
| | - Guangyong Zou
- From the Department of Inflammation and Immunity, Lerner Research
Institute (F.R., R.O., N.A.), Department of Gastroenterology, Hepatology and
Nutrition, Digestive Diseases (F.R., M.T.S., V.C.S.), and Program for Global
Translational Inflammatory Bowel Disease Research (F.R., R.O.), Cleveland Clinic
Foundation, Cleveland, Ohio; Section of Abdominal Imaging, Imaging, Digestive
Diseases and Surgery and Cancer Institutes (M.E.B.) and Department of Diagnostic
Radiology (J.M.R.) Cleveland Clinic Foundation, Cleveland, Ohio; Division of
Gastroenterology and Hepatology (D.H.B.), Biomedical Imaging Resource (D.R.H.),
and Department of Radiology (J.L.F., E.C.E., S.P.S., J.P.H., D.R.H., Y.S.L.,
J.G.F.), Mayo Clinic, 200 First St, Rochester, MN 55905; Department of
Radiology, Shiga University of Medical Science, Shiga, Japan (A.I.); Department
of Radiology, University of Texas Medical Branch, Galveston, Tex (P.M.); Centre
for Medical Imaging, University College London, London, United Kingdom (S.A.T.);
Department of Radiology and Nuclear Medicine, Amsterdam University Medical
Centre, University of Amsterdam, Amsterdam, the Netherlands (J.S.); Alimentiv,
London, Ontario, Canada (G.Z., Z.W., J. Rémillard, C.M., C.E.P., V.J.,
B.G.F.); Department of Epidemiology and Biostatistics, Western University,
London, Ontario, Canada (G.Z., V.J., B.G.F.); Department of Quantitative Health
Sciences, Mayo Clinic, Jacksonville, Fla (R.E.C.); Division of Gastroenterology
and Hepatology, University of Calgary, Calgary, Alberta, Canada (C.M.);
Departments of Gastroenterology (J.P.) and Radiology (J. Rimola), Hospital
Clínic de Barcelona, Barcelona, Spain; and Department of Medicine,
Division of Gastroenterology, Western University, London, Ontario, Canada (V.J.,
B.G.F.)
| | - Zhongya Wang
- From the Department of Inflammation and Immunity, Lerner Research
Institute (F.R., R.O., N.A.), Department of Gastroenterology, Hepatology and
Nutrition, Digestive Diseases (F.R., M.T.S., V.C.S.), and Program for Global
Translational Inflammatory Bowel Disease Research (F.R., R.O.), Cleveland Clinic
Foundation, Cleveland, Ohio; Section of Abdominal Imaging, Imaging, Digestive
Diseases and Surgery and Cancer Institutes (M.E.B.) and Department of Diagnostic
Radiology (J.M.R.) Cleveland Clinic Foundation, Cleveland, Ohio; Division of
Gastroenterology and Hepatology (D.H.B.), Biomedical Imaging Resource (D.R.H.),
and Department of Radiology (J.L.F., E.C.E., S.P.S., J.P.H., D.R.H., Y.S.L.,
J.G.F.), Mayo Clinic, 200 First St, Rochester, MN 55905; Department of
Radiology, Shiga University of Medical Science, Shiga, Japan (A.I.); Department
of Radiology, University of Texas Medical Branch, Galveston, Tex (P.M.); Centre
for Medical Imaging, University College London, London, United Kingdom (S.A.T.);
Department of Radiology and Nuclear Medicine, Amsterdam University Medical
Centre, University of Amsterdam, Amsterdam, the Netherlands (J.S.); Alimentiv,
London, Ontario, Canada (G.Z., Z.W., J. Rémillard, C.M., C.E.P., V.J.,
B.G.F.); Department of Epidemiology and Biostatistics, Western University,
London, Ontario, Canada (G.Z., V.J., B.G.F.); Department of Quantitative Health
Sciences, Mayo Clinic, Jacksonville, Fla (R.E.C.); Division of Gastroenterology
and Hepatology, University of Calgary, Calgary, Alberta, Canada (C.M.);
Departments of Gastroenterology (J.P.) and Radiology (J. Rimola), Hospital
Clínic de Barcelona, Barcelona, Spain; and Department of Medicine,
Division of Gastroenterology, Western University, London, Ontario, Canada (V.J.,
B.G.F.)
| | - Julie Rémillard
- From the Department of Inflammation and Immunity, Lerner Research
Institute (F.R., R.O., N.A.), Department of Gastroenterology, Hepatology and
Nutrition, Digestive Diseases (F.R., M.T.S., V.C.S.), and Program for Global
Translational Inflammatory Bowel Disease Research (F.R., R.O.), Cleveland Clinic
Foundation, Cleveland, Ohio; Section of Abdominal Imaging, Imaging, Digestive
Diseases and Surgery and Cancer Institutes (M.E.B.) and Department of Diagnostic
Radiology (J.M.R.) Cleveland Clinic Foundation, Cleveland, Ohio; Division of
Gastroenterology and Hepatology (D.H.B.), Biomedical Imaging Resource (D.R.H.),
and Department of Radiology (J.L.F., E.C.E., S.P.S., J.P.H., D.R.H., Y.S.L.,
J.G.F.), Mayo Clinic, 200 First St, Rochester, MN 55905; Department of
Radiology, Shiga University of Medical Science, Shiga, Japan (A.I.); Department
of Radiology, University of Texas Medical Branch, Galveston, Tex (P.M.); Centre
for Medical Imaging, University College London, London, United Kingdom (S.A.T.);
Department of Radiology and Nuclear Medicine, Amsterdam University Medical
Centre, University of Amsterdam, Amsterdam, the Netherlands (J.S.); Alimentiv,
London, Ontario, Canada (G.Z., Z.W., J. Rémillard, C.M., C.E.P., V.J.,
B.G.F.); Department of Epidemiology and Biostatistics, Western University,
London, Ontario, Canada (G.Z., V.J., B.G.F.); Department of Quantitative Health
Sciences, Mayo Clinic, Jacksonville, Fla (R.E.C.); Division of Gastroenterology
and Hepatology, University of Calgary, Calgary, Alberta, Canada (C.M.);
Departments of Gastroenterology (J.P.) and Radiology (J. Rimola), Hospital
Clínic de Barcelona, Barcelona, Spain; and Department of Medicine,
Division of Gastroenterology, Western University, London, Ontario, Canada (V.J.,
B.G.F.)
| | - Rickey E. Carter
- From the Department of Inflammation and Immunity, Lerner Research
Institute (F.R., R.O., N.A.), Department of Gastroenterology, Hepatology and
Nutrition, Digestive Diseases (F.R., M.T.S., V.C.S.), and Program for Global
Translational Inflammatory Bowel Disease Research (F.R., R.O.), Cleveland Clinic
Foundation, Cleveland, Ohio; Section of Abdominal Imaging, Imaging, Digestive
Diseases and Surgery and Cancer Institutes (M.E.B.) and Department of Diagnostic
Radiology (J.M.R.) Cleveland Clinic Foundation, Cleveland, Ohio; Division of
Gastroenterology and Hepatology (D.H.B.), Biomedical Imaging Resource (D.R.H.),
and Department of Radiology (J.L.F., E.C.E., S.P.S., J.P.H., D.R.H., Y.S.L.,
J.G.F.), Mayo Clinic, 200 First St, Rochester, MN 55905; Department of
Radiology, Shiga University of Medical Science, Shiga, Japan (A.I.); Department
of Radiology, University of Texas Medical Branch, Galveston, Tex (P.M.); Centre
for Medical Imaging, University College London, London, United Kingdom (S.A.T.);
Department of Radiology and Nuclear Medicine, Amsterdam University Medical
Centre, University of Amsterdam, Amsterdam, the Netherlands (J.S.); Alimentiv,
London, Ontario, Canada (G.Z., Z.W., J. Rémillard, C.M., C.E.P., V.J.,
B.G.F.); Department of Epidemiology and Biostatistics, Western University,
London, Ontario, Canada (G.Z., V.J., B.G.F.); Department of Quantitative Health
Sciences, Mayo Clinic, Jacksonville, Fla (R.E.C.); Division of Gastroenterology
and Hepatology, University of Calgary, Calgary, Alberta, Canada (C.M.);
Departments of Gastroenterology (J.P.) and Radiology (J. Rimola), Hospital
Clínic de Barcelona, Barcelona, Spain; and Department of Medicine,
Division of Gastroenterology, Western University, London, Ontario, Canada (V.J.,
B.G.F.)
| | - Ronald Ottichilo
- From the Department of Inflammation and Immunity, Lerner Research
Institute (F.R., R.O., N.A.), Department of Gastroenterology, Hepatology and
Nutrition, Digestive Diseases (F.R., M.T.S., V.C.S.), and Program for Global
Translational Inflammatory Bowel Disease Research (F.R., R.O.), Cleveland Clinic
Foundation, Cleveland, Ohio; Section of Abdominal Imaging, Imaging, Digestive
Diseases and Surgery and Cancer Institutes (M.E.B.) and Department of Diagnostic
Radiology (J.M.R.) Cleveland Clinic Foundation, Cleveland, Ohio; Division of
Gastroenterology and Hepatology (D.H.B.), Biomedical Imaging Resource (D.R.H.),
and Department of Radiology (J.L.F., E.C.E., S.P.S., J.P.H., D.R.H., Y.S.L.,
J.G.F.), Mayo Clinic, 200 First St, Rochester, MN 55905; Department of
Radiology, Shiga University of Medical Science, Shiga, Japan (A.I.); Department
of Radiology, University of Texas Medical Branch, Galveston, Tex (P.M.); Centre
for Medical Imaging, University College London, London, United Kingdom (S.A.T.);
Department of Radiology and Nuclear Medicine, Amsterdam University Medical
Centre, University of Amsterdam, Amsterdam, the Netherlands (J.S.); Alimentiv,
London, Ontario, Canada (G.Z., Z.W., J. Rémillard, C.M., C.E.P., V.J.,
B.G.F.); Department of Epidemiology and Biostatistics, Western University,
London, Ontario, Canada (G.Z., V.J., B.G.F.); Department of Quantitative Health
Sciences, Mayo Clinic, Jacksonville, Fla (R.E.C.); Division of Gastroenterology
and Hepatology, University of Calgary, Calgary, Alberta, Canada (C.M.);
Departments of Gastroenterology (J.P.) and Radiology (J. Rimola), Hospital
Clínic de Barcelona, Barcelona, Spain; and Department of Medicine,
Division of Gastroenterology, Western University, London, Ontario, Canada (V.J.,
B.G.F.)
| | - Norma Atkinson
- From the Department of Inflammation and Immunity, Lerner Research
Institute (F.R., R.O., N.A.), Department of Gastroenterology, Hepatology and
Nutrition, Digestive Diseases (F.R., M.T.S., V.C.S.), and Program for Global
Translational Inflammatory Bowel Disease Research (F.R., R.O.), Cleveland Clinic
Foundation, Cleveland, Ohio; Section of Abdominal Imaging, Imaging, Digestive
Diseases and Surgery and Cancer Institutes (M.E.B.) and Department of Diagnostic
Radiology (J.M.R.) Cleveland Clinic Foundation, Cleveland, Ohio; Division of
Gastroenterology and Hepatology (D.H.B.), Biomedical Imaging Resource (D.R.H.),
and Department of Radiology (J.L.F., E.C.E., S.P.S., J.P.H., D.R.H., Y.S.L.,
J.G.F.), Mayo Clinic, 200 First St, Rochester, MN 55905; Department of
Radiology, Shiga University of Medical Science, Shiga, Japan (A.I.); Department
of Radiology, University of Texas Medical Branch, Galveston, Tex (P.M.); Centre
for Medical Imaging, University College London, London, United Kingdom (S.A.T.);
Department of Radiology and Nuclear Medicine, Amsterdam University Medical
Centre, University of Amsterdam, Amsterdam, the Netherlands (J.S.); Alimentiv,
London, Ontario, Canada (G.Z., Z.W., J. Rémillard, C.M., C.E.P., V.J.,
B.G.F.); Department of Epidemiology and Biostatistics, Western University,
London, Ontario, Canada (G.Z., V.J., B.G.F.); Department of Quantitative Health
Sciences, Mayo Clinic, Jacksonville, Fla (R.E.C.); Division of Gastroenterology
and Hepatology, University of Calgary, Calgary, Alberta, Canada (C.M.);
Departments of Gastroenterology (J.P.) and Radiology (J. Rimola), Hospital
Clínic de Barcelona, Barcelona, Spain; and Department of Medicine,
Division of Gastroenterology, Western University, London, Ontario, Canada (V.J.,
B.G.F.)
| | - Mohamed Tausif Siddiqui
- From the Department of Inflammation and Immunity, Lerner Research
Institute (F.R., R.O., N.A.), Department of Gastroenterology, Hepatology and
Nutrition, Digestive Diseases (F.R., M.T.S., V.C.S.), and Program for Global
Translational Inflammatory Bowel Disease Research (F.R., R.O.), Cleveland Clinic
Foundation, Cleveland, Ohio; Section of Abdominal Imaging, Imaging, Digestive
Diseases and Surgery and Cancer Institutes (M.E.B.) and Department of Diagnostic
Radiology (J.M.R.) Cleveland Clinic Foundation, Cleveland, Ohio; Division of
Gastroenterology and Hepatology (D.H.B.), Biomedical Imaging Resource (D.R.H.),
and Department of Radiology (J.L.F., E.C.E., S.P.S., J.P.H., D.R.H., Y.S.L.,
J.G.F.), Mayo Clinic, 200 First St, Rochester, MN 55905; Department of
Radiology, Shiga University of Medical Science, Shiga, Japan (A.I.); Department
of Radiology, University of Texas Medical Branch, Galveston, Tex (P.M.); Centre
for Medical Imaging, University College London, London, United Kingdom (S.A.T.);
Department of Radiology and Nuclear Medicine, Amsterdam University Medical
Centre, University of Amsterdam, Amsterdam, the Netherlands (J.S.); Alimentiv,
London, Ontario, Canada (G.Z., Z.W., J. Rémillard, C.M., C.E.P., V.J.,
B.G.F.); Department of Epidemiology and Biostatistics, Western University,
London, Ontario, Canada (G.Z., V.J., B.G.F.); Department of Quantitative Health
Sciences, Mayo Clinic, Jacksonville, Fla (R.E.C.); Division of Gastroenterology
and Hepatology, University of Calgary, Calgary, Alberta, Canada (C.M.);
Departments of Gastroenterology (J.P.) and Radiology (J. Rimola), Hospital
Clínic de Barcelona, Barcelona, Spain; and Department of Medicine,
Division of Gastroenterology, Western University, London, Ontario, Canada (V.J.,
B.G.F.)
| | - Venkata C. Sunkesula
- From the Department of Inflammation and Immunity, Lerner Research
Institute (F.R., R.O., N.A.), Department of Gastroenterology, Hepatology and
Nutrition, Digestive Diseases (F.R., M.T.S., V.C.S.), and Program for Global
Translational Inflammatory Bowel Disease Research (F.R., R.O.), Cleveland Clinic
Foundation, Cleveland, Ohio; Section of Abdominal Imaging, Imaging, Digestive
Diseases and Surgery and Cancer Institutes (M.E.B.) and Department of Diagnostic
Radiology (J.M.R.) Cleveland Clinic Foundation, Cleveland, Ohio; Division of
Gastroenterology and Hepatology (D.H.B.), Biomedical Imaging Resource (D.R.H.),
and Department of Radiology (J.L.F., E.C.E., S.P.S., J.P.H., D.R.H., Y.S.L.,
J.G.F.), Mayo Clinic, 200 First St, Rochester, MN 55905; Department of
Radiology, Shiga University of Medical Science, Shiga, Japan (A.I.); Department
of Radiology, University of Texas Medical Branch, Galveston, Tex (P.M.); Centre
for Medical Imaging, University College London, London, United Kingdom (S.A.T.);
Department of Radiology and Nuclear Medicine, Amsterdam University Medical
Centre, University of Amsterdam, Amsterdam, the Netherlands (J.S.); Alimentiv,
London, Ontario, Canada (G.Z., Z.W., J. Rémillard, C.M., C.E.P., V.J.,
B.G.F.); Department of Epidemiology and Biostatistics, Western University,
London, Ontario, Canada (G.Z., V.J., B.G.F.); Department of Quantitative Health
Sciences, Mayo Clinic, Jacksonville, Fla (R.E.C.); Division of Gastroenterology
and Hepatology, University of Calgary, Calgary, Alberta, Canada (C.M.);
Departments of Gastroenterology (J.P.) and Radiology (J. Rimola), Hospital
Clínic de Barcelona, Barcelona, Spain; and Department of Medicine,
Division of Gastroenterology, Western University, London, Ontario, Canada (V.J.,
B.G.F.)
| | - Christopher Ma
- From the Department of Inflammation and Immunity, Lerner Research
Institute (F.R., R.O., N.A.), Department of Gastroenterology, Hepatology and
Nutrition, Digestive Diseases (F.R., M.T.S., V.C.S.), and Program for Global
Translational Inflammatory Bowel Disease Research (F.R., R.O.), Cleveland Clinic
Foundation, Cleveland, Ohio; Section of Abdominal Imaging, Imaging, Digestive
Diseases and Surgery and Cancer Institutes (M.E.B.) and Department of Diagnostic
Radiology (J.M.R.) Cleveland Clinic Foundation, Cleveland, Ohio; Division of
Gastroenterology and Hepatology (D.H.B.), Biomedical Imaging Resource (D.R.H.),
and Department of Radiology (J.L.F., E.C.E., S.P.S., J.P.H., D.R.H., Y.S.L.,
J.G.F.), Mayo Clinic, 200 First St, Rochester, MN 55905; Department of
Radiology, Shiga University of Medical Science, Shiga, Japan (A.I.); Department
of Radiology, University of Texas Medical Branch, Galveston, Tex (P.M.); Centre
for Medical Imaging, University College London, London, United Kingdom (S.A.T.);
Department of Radiology and Nuclear Medicine, Amsterdam University Medical
Centre, University of Amsterdam, Amsterdam, the Netherlands (J.S.); Alimentiv,
London, Ontario, Canada (G.Z., Z.W., J. Rémillard, C.M., C.E.P., V.J.,
B.G.F.); Department of Epidemiology and Biostatistics, Western University,
London, Ontario, Canada (G.Z., V.J., B.G.F.); Department of Quantitative Health
Sciences, Mayo Clinic, Jacksonville, Fla (R.E.C.); Division of Gastroenterology
and Hepatology, University of Calgary, Calgary, Alberta, Canada (C.M.);
Departments of Gastroenterology (J.P.) and Radiology (J. Rimola), Hospital
Clínic de Barcelona, Barcelona, Spain; and Department of Medicine,
Division of Gastroenterology, Western University, London, Ontario, Canada (V.J.,
B.G.F.)
| | - Claire E. Parker
- From the Department of Inflammation and Immunity, Lerner Research
Institute (F.R., R.O., N.A.), Department of Gastroenterology, Hepatology and
Nutrition, Digestive Diseases (F.R., M.T.S., V.C.S.), and Program for Global
Translational Inflammatory Bowel Disease Research (F.R., R.O.), Cleveland Clinic
Foundation, Cleveland, Ohio; Section of Abdominal Imaging, Imaging, Digestive
Diseases and Surgery and Cancer Institutes (M.E.B.) and Department of Diagnostic
Radiology (J.M.R.) Cleveland Clinic Foundation, Cleveland, Ohio; Division of
Gastroenterology and Hepatology (D.H.B.), Biomedical Imaging Resource (D.R.H.),
and Department of Radiology (J.L.F., E.C.E., S.P.S., J.P.H., D.R.H., Y.S.L.,
J.G.F.), Mayo Clinic, 200 First St, Rochester, MN 55905; Department of
Radiology, Shiga University of Medical Science, Shiga, Japan (A.I.); Department
of Radiology, University of Texas Medical Branch, Galveston, Tex (P.M.); Centre
for Medical Imaging, University College London, London, United Kingdom (S.A.T.);
Department of Radiology and Nuclear Medicine, Amsterdam University Medical
Centre, University of Amsterdam, Amsterdam, the Netherlands (J.S.); Alimentiv,
London, Ontario, Canada (G.Z., Z.W., J. Rémillard, C.M., C.E.P., V.J.,
B.G.F.); Department of Epidemiology and Biostatistics, Western University,
London, Ontario, Canada (G.Z., V.J., B.G.F.); Department of Quantitative Health
Sciences, Mayo Clinic, Jacksonville, Fla (R.E.C.); Division of Gastroenterology
and Hepatology, University of Calgary, Calgary, Alberta, Canada (C.M.);
Departments of Gastroenterology (J.P.) and Radiology (J. Rimola), Hospital
Clínic de Barcelona, Barcelona, Spain; and Department of Medicine,
Division of Gastroenterology, Western University, London, Ontario, Canada (V.J.,
B.G.F.)
| | - Julian Panés
- From the Department of Inflammation and Immunity, Lerner Research
Institute (F.R., R.O., N.A.), Department of Gastroenterology, Hepatology and
Nutrition, Digestive Diseases (F.R., M.T.S., V.C.S.), and Program for Global
Translational Inflammatory Bowel Disease Research (F.R., R.O.), Cleveland Clinic
Foundation, Cleveland, Ohio; Section of Abdominal Imaging, Imaging, Digestive
Diseases and Surgery and Cancer Institutes (M.E.B.) and Department of Diagnostic
Radiology (J.M.R.) Cleveland Clinic Foundation, Cleveland, Ohio; Division of
Gastroenterology and Hepatology (D.H.B.), Biomedical Imaging Resource (D.R.H.),
and Department of Radiology (J.L.F., E.C.E., S.P.S., J.P.H., D.R.H., Y.S.L.,
J.G.F.), Mayo Clinic, 200 First St, Rochester, MN 55905; Department of
Radiology, Shiga University of Medical Science, Shiga, Japan (A.I.); Department
of Radiology, University of Texas Medical Branch, Galveston, Tex (P.M.); Centre
for Medical Imaging, University College London, London, United Kingdom (S.A.T.);
Department of Radiology and Nuclear Medicine, Amsterdam University Medical
Centre, University of Amsterdam, Amsterdam, the Netherlands (J.S.); Alimentiv,
London, Ontario, Canada (G.Z., Z.W., J. Rémillard, C.M., C.E.P., V.J.,
B.G.F.); Department of Epidemiology and Biostatistics, Western University,
London, Ontario, Canada (G.Z., V.J., B.G.F.); Department of Quantitative Health
Sciences, Mayo Clinic, Jacksonville, Fla (R.E.C.); Division of Gastroenterology
and Hepatology, University of Calgary, Calgary, Alberta, Canada (C.M.);
Departments of Gastroenterology (J.P.) and Radiology (J. Rimola), Hospital
Clínic de Barcelona, Barcelona, Spain; and Department of Medicine,
Division of Gastroenterology, Western University, London, Ontario, Canada (V.J.,
B.G.F.)
| | - Jordi Rimola
- From the Department of Inflammation and Immunity, Lerner Research
Institute (F.R., R.O., N.A.), Department of Gastroenterology, Hepatology and
Nutrition, Digestive Diseases (F.R., M.T.S., V.C.S.), and Program for Global
Translational Inflammatory Bowel Disease Research (F.R., R.O.), Cleveland Clinic
Foundation, Cleveland, Ohio; Section of Abdominal Imaging, Imaging, Digestive
Diseases and Surgery and Cancer Institutes (M.E.B.) and Department of Diagnostic
Radiology (J.M.R.) Cleveland Clinic Foundation, Cleveland, Ohio; Division of
Gastroenterology and Hepatology (D.H.B.), Biomedical Imaging Resource (D.R.H.),
and Department of Radiology (J.L.F., E.C.E., S.P.S., J.P.H., D.R.H., Y.S.L.,
J.G.F.), Mayo Clinic, 200 First St, Rochester, MN 55905; Department of
Radiology, Shiga University of Medical Science, Shiga, Japan (A.I.); Department
of Radiology, University of Texas Medical Branch, Galveston, Tex (P.M.); Centre
for Medical Imaging, University College London, London, United Kingdom (S.A.T.);
Department of Radiology and Nuclear Medicine, Amsterdam University Medical
Centre, University of Amsterdam, Amsterdam, the Netherlands (J.S.); Alimentiv,
London, Ontario, Canada (G.Z., Z.W., J. Rémillard, C.M., C.E.P., V.J.,
B.G.F.); Department of Epidemiology and Biostatistics, Western University,
London, Ontario, Canada (G.Z., V.J., B.G.F.); Department of Quantitative Health
Sciences, Mayo Clinic, Jacksonville, Fla (R.E.C.); Division of Gastroenterology
and Hepatology, University of Calgary, Calgary, Alberta, Canada (C.M.);
Departments of Gastroenterology (J.P.) and Radiology (J. Rimola), Hospital
Clínic de Barcelona, Barcelona, Spain; and Department of Medicine,
Division of Gastroenterology, Western University, London, Ontario, Canada (V.J.,
B.G.F.)
| | - Vipul Jairath
- From the Department of Inflammation and Immunity, Lerner Research
Institute (F.R., R.O., N.A.), Department of Gastroenterology, Hepatology and
Nutrition, Digestive Diseases (F.R., M.T.S., V.C.S.), and Program for Global
Translational Inflammatory Bowel Disease Research (F.R., R.O.), Cleveland Clinic
Foundation, Cleveland, Ohio; Section of Abdominal Imaging, Imaging, Digestive
Diseases and Surgery and Cancer Institutes (M.E.B.) and Department of Diagnostic
Radiology (J.M.R.) Cleveland Clinic Foundation, Cleveland, Ohio; Division of
Gastroenterology and Hepatology (D.H.B.), Biomedical Imaging Resource (D.R.H.),
and Department of Radiology (J.L.F., E.C.E., S.P.S., J.P.H., D.R.H., Y.S.L.,
J.G.F.), Mayo Clinic, 200 First St, Rochester, MN 55905; Department of
Radiology, Shiga University of Medical Science, Shiga, Japan (A.I.); Department
of Radiology, University of Texas Medical Branch, Galveston, Tex (P.M.); Centre
for Medical Imaging, University College London, London, United Kingdom (S.A.T.);
Department of Radiology and Nuclear Medicine, Amsterdam University Medical
Centre, University of Amsterdam, Amsterdam, the Netherlands (J.S.); Alimentiv,
London, Ontario, Canada (G.Z., Z.W., J. Rémillard, C.M., C.E.P., V.J.,
B.G.F.); Department of Epidemiology and Biostatistics, Western University,
London, Ontario, Canada (G.Z., V.J., B.G.F.); Department of Quantitative Health
Sciences, Mayo Clinic, Jacksonville, Fla (R.E.C.); Division of Gastroenterology
and Hepatology, University of Calgary, Calgary, Alberta, Canada (C.M.);
Departments of Gastroenterology (J.P.) and Radiology (J. Rimola), Hospital
Clínic de Barcelona, Barcelona, Spain; and Department of Medicine,
Division of Gastroenterology, Western University, London, Ontario, Canada (V.J.,
B.G.F.)
| | - Brian G. Feagan
- From the Department of Inflammation and Immunity, Lerner Research
Institute (F.R., R.O., N.A.), Department of Gastroenterology, Hepatology and
Nutrition, Digestive Diseases (F.R., M.T.S., V.C.S.), and Program for Global
Translational Inflammatory Bowel Disease Research (F.R., R.O.), Cleveland Clinic
Foundation, Cleveland, Ohio; Section of Abdominal Imaging, Imaging, Digestive
Diseases and Surgery and Cancer Institutes (M.E.B.) and Department of Diagnostic
Radiology (J.M.R.) Cleveland Clinic Foundation, Cleveland, Ohio; Division of
Gastroenterology and Hepatology (D.H.B.), Biomedical Imaging Resource (D.R.H.),
and Department of Radiology (J.L.F., E.C.E., S.P.S., J.P.H., D.R.H., Y.S.L.,
J.G.F.), Mayo Clinic, 200 First St, Rochester, MN 55905; Department of
Radiology, Shiga University of Medical Science, Shiga, Japan (A.I.); Department
of Radiology, University of Texas Medical Branch, Galveston, Tex (P.M.); Centre
for Medical Imaging, University College London, London, United Kingdom (S.A.T.);
Department of Radiology and Nuclear Medicine, Amsterdam University Medical
Centre, University of Amsterdam, Amsterdam, the Netherlands (J.S.); Alimentiv,
London, Ontario, Canada (G.Z., Z.W., J. Rémillard, C.M., C.E.P., V.J.,
B.G.F.); Department of Epidemiology and Biostatistics, Western University,
London, Ontario, Canada (G.Z., V.J., B.G.F.); Department of Quantitative Health
Sciences, Mayo Clinic, Jacksonville, Fla (R.E.C.); Division of Gastroenterology
and Hepatology, University of Calgary, Calgary, Alberta, Canada (C.M.);
Departments of Gastroenterology (J.P.) and Radiology (J. Rimola), Hospital
Clínic de Barcelona, Barcelona, Spain; and Department of Medicine,
Division of Gastroenterology, Western University, London, Ontario, Canada (V.J.,
B.G.F.)
| | - Joel G. Fletcher
- From the Department of Inflammation and Immunity, Lerner Research
Institute (F.R., R.O., N.A.), Department of Gastroenterology, Hepatology and
Nutrition, Digestive Diseases (F.R., M.T.S., V.C.S.), and Program for Global
Translational Inflammatory Bowel Disease Research (F.R., R.O.), Cleveland Clinic
Foundation, Cleveland, Ohio; Section of Abdominal Imaging, Imaging, Digestive
Diseases and Surgery and Cancer Institutes (M.E.B.) and Department of Diagnostic
Radiology (J.M.R.) Cleveland Clinic Foundation, Cleveland, Ohio; Division of
Gastroenterology and Hepatology (D.H.B.), Biomedical Imaging Resource (D.R.H.),
and Department of Radiology (J.L.F., E.C.E., S.P.S., J.P.H., D.R.H., Y.S.L.,
J.G.F.), Mayo Clinic, 200 First St, Rochester, MN 55905; Department of
Radiology, Shiga University of Medical Science, Shiga, Japan (A.I.); Department
of Radiology, University of Texas Medical Branch, Galveston, Tex (P.M.); Centre
for Medical Imaging, University College London, London, United Kingdom (S.A.T.);
Department of Radiology and Nuclear Medicine, Amsterdam University Medical
Centre, University of Amsterdam, Amsterdam, the Netherlands (J.S.); Alimentiv,
London, Ontario, Canada (G.Z., Z.W., J. Rémillard, C.M., C.E.P., V.J.,
B.G.F.); Department of Epidemiology and Biostatistics, Western University,
London, Ontario, Canada (G.Z., V.J., B.G.F.); Department of Quantitative Health
Sciences, Mayo Clinic, Jacksonville, Fla (R.E.C.); Division of Gastroenterology
and Hepatology, University of Calgary, Calgary, Alberta, Canada (C.M.);
Departments of Gastroenterology (J.P.) and Radiology (J. Rimola), Hospital
Clínic de Barcelona, Barcelona, Spain; and Department of Medicine,
Division of Gastroenterology, Western University, London, Ontario, Canada (V.J.,
B.G.F.)
| | - for the Stenosis Therapy and Anti-Fibrosis Research (STAR)
Consortium
- From the Department of Inflammation and Immunity, Lerner Research
Institute (F.R., R.O., N.A.), Department of Gastroenterology, Hepatology and
Nutrition, Digestive Diseases (F.R., M.T.S., V.C.S.), and Program for Global
Translational Inflammatory Bowel Disease Research (F.R., R.O.), Cleveland Clinic
Foundation, Cleveland, Ohio; Section of Abdominal Imaging, Imaging, Digestive
Diseases and Surgery and Cancer Institutes (M.E.B.) and Department of Diagnostic
Radiology (J.M.R.) Cleveland Clinic Foundation, Cleveland, Ohio; Division of
Gastroenterology and Hepatology (D.H.B.), Biomedical Imaging Resource (D.R.H.),
and Department of Radiology (J.L.F., E.C.E., S.P.S., J.P.H., D.R.H., Y.S.L.,
J.G.F.), Mayo Clinic, 200 First St, Rochester, MN 55905; Department of
Radiology, Shiga University of Medical Science, Shiga, Japan (A.I.); Department
of Radiology, University of Texas Medical Branch, Galveston, Tex (P.M.); Centre
for Medical Imaging, University College London, London, United Kingdom (S.A.T.);
Department of Radiology and Nuclear Medicine, Amsterdam University Medical
Centre, University of Amsterdam, Amsterdam, the Netherlands (J.S.); Alimentiv,
London, Ontario, Canada (G.Z., Z.W., J. Rémillard, C.M., C.E.P., V.J.,
B.G.F.); Department of Epidemiology and Biostatistics, Western University,
London, Ontario, Canada (G.Z., V.J., B.G.F.); Department of Quantitative Health
Sciences, Mayo Clinic, Jacksonville, Fla (R.E.C.); Division of Gastroenterology
and Hepatology, University of Calgary, Calgary, Alberta, Canada (C.M.);
Departments of Gastroenterology (J.P.) and Radiology (J. Rimola), Hospital
Clínic de Barcelona, Barcelona, Spain; and Department of Medicine,
Division of Gastroenterology, Western University, London, Ontario, Canada (V.J.,
B.G.F.)
| | - Sarah Atzen
- From the Department of Inflammation and Immunity, Lerner Research
Institute (F.R., R.O., N.A.), Department of Gastroenterology, Hepatology and
Nutrition, Digestive Diseases (F.R., M.T.S., V.C.S.), and Program for Global
Translational Inflammatory Bowel Disease Research (F.R., R.O.), Cleveland Clinic
Foundation, Cleveland, Ohio; Section of Abdominal Imaging, Imaging, Digestive
Diseases and Surgery and Cancer Institutes (M.E.B.) and Department of Diagnostic
Radiology (J.M.R.) Cleveland Clinic Foundation, Cleveland, Ohio; Division of
Gastroenterology and Hepatology (D.H.B.), Biomedical Imaging Resource (D.R.H.),
and Department of Radiology (J.L.F., E.C.E., S.P.S., J.P.H., D.R.H., Y.S.L.,
J.G.F.), Mayo Clinic, 200 First St, Rochester, MN 55905; Department of
Radiology, Shiga University of Medical Science, Shiga, Japan (A.I.); Department
of Radiology, University of Texas Medical Branch, Galveston, Tex (P.M.); Centre
for Medical Imaging, University College London, London, United Kingdom (S.A.T.);
Department of Radiology and Nuclear Medicine, Amsterdam University Medical
Centre, University of Amsterdam, Amsterdam, the Netherlands (J.S.); Alimentiv,
London, Ontario, Canada (G.Z., Z.W., J. Rémillard, C.M., C.E.P., V.J.,
B.G.F.); Department of Epidemiology and Biostatistics, Western University,
London, Ontario, Canada (G.Z., V.J., B.G.F.); Department of Quantitative Health
Sciences, Mayo Clinic, Jacksonville, Fla (R.E.C.); Division of Gastroenterology
and Hepatology, University of Calgary, Calgary, Alberta, Canada (C.M.);
Departments of Gastroenterology (J.P.) and Radiology (J. Rimola), Hospital
Clínic de Barcelona, Barcelona, Spain; and Department of Medicine,
Division of Gastroenterology, Western University, London, Ontario, Canada (V.J.,
B.G.F.)
| |
Collapse
|
12
|
Mignini I, Blasi V, Termite F, Esposto G, Borriello R, Laterza L, Scaldaferri F, Ainora ME, Gasbarrini A, Zocco MA. Fibrostenosing Crohn's Disease: Pathogenetic Mechanisms and New Therapeutic Horizons. Int J Mol Sci 2024; 25:6326. [PMID: 38928032 PMCID: PMC11204249 DOI: 10.3390/ijms25126326] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2024] [Revised: 05/30/2024] [Accepted: 06/04/2024] [Indexed: 06/28/2024] Open
Abstract
Bowel strictures are well recognized as one of the most severe complications in Crohn's disease, with variable impacts on the prognosis and often needing surgical or endoscopic treatment. Distinguishing inflammatory strictures from fibrotic ones is of primary importance due to the different therapeutic approaches required. Indeed, to better understand the pathogenesis of fibrosis, it is crucial to investigate molecular processes involving genetic factors, cytokines, alteration of the intestinal barrier, and epithelial and endothelial damage, leading to an increase in extracellular matrix synthesis, which ultimately ends in fibrosis. In such a complex mechanism, the gut microbiota also seems to play a role. A better comprehension of molecular processes underlying bowel fibrosis, in addition to radiological and histopathological findings, has led to the identification of high-risk patients for personalized follow-up and testing of new therapies, primarily in preclinical models, targeting specific pathways involving Transforming Growth Factor-β, interleukins, extracellular matrix balance, and gut microbiota. Our review aims to summarize current evidence about molecular factors involved in intestinal fibrosis' pathogenesis, paving the way for potential diagnostic biomarkers or anti-fibrotic treatments for stricturing Crohn's disease.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | - Maria Assunta Zocco
- CEMAD Digestive Diseases Center, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Università Cattolica del Sacro Cuore, Largo A. Gemelli 8, 00168 Rome, Italy; (I.M.); (V.B.); (G.E.); (R.B.); (L.L.); (F.S.); (M.E.A.); (A.G.)
| |
Collapse
|
13
|
Adolph TE. It is in the matrix: a molecular clue to fibro-stenotic Crohn's disease. Gut 2024; 73:1045-1046. [PMID: 38378251 DOI: 10.1136/gutjnl-2024-332016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/30/2024] [Accepted: 02/05/2024] [Indexed: 02/22/2024]
Affiliation(s)
- Timon E Adolph
- Internal Medicine I, Medizinische Universitat Innsbruck, Innsbruck, Austria
| |
Collapse
|
14
|
Steiner CA, Colgan SP. Authors' Reply. THE AMERICAN JOURNAL OF PATHOLOGY 2024; 194:1156-1157. [PMID: 38749611 PMCID: PMC11156156 DOI: 10.1016/j.ajpath.2024.03.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/07/2024] [Accepted: 03/20/2024] [Indexed: 06/07/2024]
Affiliation(s)
- Calen A Steiner
- Division of Gastroenterology and Hepatology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado; Mucosal Inflammation Program, University of Colorado School of Medicine, Aurora, Colorado.
| | - Sean P Colgan
- Division of Gastroenterology and Hepatology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado; Mucosal Inflammation Program, University of Colorado School of Medicine, Aurora, Colorado; Rocky Mountain Regional Veterans Affairs Medical Center, Aurora, Colorado
| |
Collapse
|
15
|
Lu C, Rosentreter R, Delisle M, White M, Parker CE, Premji Z, Wilson SR, Baker ME, Bhatnagar G, Begun J, Bruining DH, Bryant R, Christensen B, Feagan BG, Fletcher JG, Jairath V, Knudsen J, Kucharzik T, Maaser C, Maconi G, Novak K, Rimola J, Taylor SA, Wilkens R, Rieder F. Systematic review: Defining, diagnosing and monitoring small bowel strictures in Crohn's disease on intestinal ultrasound. Aliment Pharmacol Ther 2024; 59:928-940. [PMID: 38436124 DOI: 10.1111/apt.17918] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/06/2023] [Revised: 12/29/2023] [Accepted: 02/11/2024] [Indexed: 03/05/2024]
Abstract
BACKGROUND Stricturing Crohn's disease (CD) occurs most commonly in the terminal ileum and poses a clinical problem. Cross-sectional imaging modalities such as intestinal ultrasound (IUS), computed tomography enterography (CTE), and magnetic resonance enterography (MRE) allow for assessment of the entire bowel wall and associated peri-enteric findings. Radiologic definitions of strictures have been developed for CTE and MRE; their reliability and responsiveness are being evaluated in index development programs. A comprehensive assessment strategy for strictures using IUS is needed. AIMS To provide a detailed summary of definitions, diagnosis and monitoring of strictures on IUS as well as technical aspects of image acquisition. METHODS We searched four databases up to 6 January 2024. Two-stage screening was done in duplicate. We assessed risk of bias using QUADAS-2. RESULTS There were 56 studies eligible for inclusion. Definitions for strictures on IUS are heterogeneous, but the overall accuracy for diagnosis of strictures is high. The capability of IUS for characterising inflammation versus fibrosis in strictures is not accurate enough to be used in clinical practice or trials. We summarise definitions for improvement of strictures on IUS, and discuss parameters for image acquisition and standardisation. CONCLUSIONS This systematic review is the first step for a structured program to develop a stricture IUS index for CD.
Collapse
Affiliation(s)
- Cathy Lu
- Division of Gastroenterology and Hepatology, University of Calgary, Calgary, Alberta, Canada
| | - Ryan Rosentreter
- Division of Gastroenterology and Hepatology, University of Calgary, Calgary, Alberta, Canada
| | - Maxime Delisle
- Department of Medicine, Division of Gastroenterology, Université de Sherbrooke, Sherbrooke, Quebec, Canada
| | - Mattie White
- Department of Gastroenterology, Hepatology & Nutrition; Digestive Diseases and Surgery Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA
| | | | - Zahra Premji
- Libraries, University of Victoria, Victoria, British Columbia, Canada
| | - Stephanie R Wilson
- Division of Gastroenterology and Hepatology, University of Calgary, Calgary, Alberta, Canada
- Department of Radiology, University of Calgary, Calgary, Alberta, Canada
| | - Mark E Baker
- Imaging Institute, Cleveland Clinic, Cleveland, Ohio, USA
| | - Gauraang Bhatnagar
- Centre for Medical Imaging, University College London, London, UK
- Frimley Health NHS Foundation Trust, Surrey, UK
| | - Jakob Begun
- Department of Gastroenterology, Mater Hospital, Brisbane, Queensland, Australia
| | - David H Bruining
- Department of Gastroenterology, Queen Elizabeth Hospital, Adelaide, South Australia
| | - Robert Bryant
- Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
| | - Britt Christensen
- Department of Gastroenterology, Royal Melbourne Hospital and University of Melbourne, Melbourne, Victoria, Australia
| | - Brian G Feagan
- Alimentiv Inc., London, Ontario, Canada
- Department of Medicine, University of Western Ontario, London, Ontario, Canada
| | - Joel G Fletcher
- Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA
| | - Vipul Jairath
- Alimentiv Inc., London, Ontario, Canada
- Department of Medicine, University of Western Ontario, London, Ontario, Canada
- Department of Epidemiology and Biostatistics, Department of Medicine, Western University, London, Ontario, Canada
| | - John Knudsen
- Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA
| | - Torsten Kucharzik
- Department of General Internal Medicine and Gastroenterology, University Teaching Hospital Lüneburg, Lüneburg, Germany
| | - Christian Maaser
- Outpatients' Department of Gastroenterology, University Teaching Hospital Lüneburg, Lüneberg, Germany
| | - Giovanni Maconi
- Gastroenterology Unit, Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy
| | - Kerri Novak
- Division of Gastroenterology and Hepatology, University of Calgary, Calgary, Alberta, Canada
| | - Jordi Rimola
- IBD Unit, Radiology Department, Hospital Clinic Barcelona, IDIBAPS, Barcelona, Spain
| | - Stuart A Taylor
- Centre for Medical Imaging, University College London, London, UK
| | - Rune Wilkens
- Digestive Disease Center, Copenhagen University Hospital-Bispebjerg, Copenhagen, Denmark
- Copenhagen Intestinal Ultrasound, Bispebjerg Hospital, Copenhagen, Denmark
| | - Florian Rieder
- Department of Gastroenterology, Hepatology & Nutrition; Digestive Diseases and Surgery Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA
- Cleveland Clinic Center for Global Translational Inflammatory Bowel Diseases, Cleveland, Ohio, USA
- Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA
| |
Collapse
|
16
|
Rimola J, Beek KJ, Ordás I, Gecse KB, Cuatrecasas M, Stoker J. Contemporary Imaging Assessment of Strictures and Fibrosis in Crohn Disease, With Focus on Quantitative Biomarkers: From the AJR Special Series on Imaging of Fibrosis. AJR Am J Roentgenol 2024; 222:e2329693. [PMID: 37530400 DOI: 10.2214/ajr.23.29693] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/03/2023]
Abstract
Patients with Crohn disease commonly have bowel strictures develop, which exhibit varying degrees of inflammation and fibrosis. Differentiation of the distinct inflammatory and fibrotic components of strictures is key for the optimization of therapeutic management and for the development of antifibrotic drugs. Cross-sectional imaging techniques, including ultrasound, CT, and MRI, allow evaluation of the full thickness of the bowel wall as well as extramural complications and associated mesenteric abnormalities. Although promising data have been reported for a range of novel imaging biomarkers for detection of fibrosis and quantification of the degree of fibrosis, these biomarkers lack sufficient validation and standardization for clinical use. Additional methods, including PET with emerging radiotracers, artificial intelligence, and radiomics, are also under investigation for stricture characterization. In this review, we highlight the clinical relevance of identifying fibrosis in Crohn disease, review the histopathologic aspects of strictures in Crohn disease, summarize the morphologic imaging findings of strictures, and explore contemporary developments in the use of cross-sectional imaging techniques for detecting and characterizing intestinal strictures, with attention given to emerging quantitative biomarkers.
Collapse
Affiliation(s)
- Jordi Rimola
- Radiology Department, IBD Unit, Hospital Clínic de Barcelona, Villarroel 170, Escala 3, Planta 1, Barcelona 08036, Spain
- Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Kim J Beek
- Department of Radiology and Nuclear Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
- Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, Amsterdam, The Netherlands
| | - Ingrid Ordás
- Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain
- Gastroenterology Department, IBD Unit, Hospital Clínic de Barcelona, Barcelona, Spain
- Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain
| | - Krisztina B Gecse
- Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, Amsterdam, The Netherlands
| | - Míriam Cuatrecasas
- Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain
- Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain
- Pathology Department, IBD Unit, Hospital Clínic de Barcelona, Barcelona, Spain
| | - Jaap Stoker
- Department of Radiology and Nuclear Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
- Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, Amsterdam, The Netherlands
| |
Collapse
|
17
|
Qiu X, Teng J, Wang N, Cao L, Cheng C, Su C, Dong Y, Wang F, Chen W. Transcriptomic analysis reveals the potential crosstalk genes and immune relationship between Crohn's disease and atrial fibrillation. J Thorac Dis 2024; 16:1247-1261. [PMID: 38505024 PMCID: PMC10944785 DOI: 10.21037/jtd-23-1078] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2023] [Accepted: 01/12/2024] [Indexed: 03/21/2024]
Abstract
Background At present, there is a paucity of research on the link between Crohn's disease (CD) and atrial fibrillation (AF). Nevertheless, both ailments are thought to entail inflammatory and autoimmune processes, and emerging evidence indicates that individuals with CD may face an elevated risk of AF. To shed light on this issue, our study seeks to explore the possibility of shared genes, pathways, and immune cells between these two conditions. Methods We retrieved the gene expression profiles of both CD and AF from the Gene Expression Omnibus (GEO) database and subjected them to analysis. Afterward, we utilized the weighted gene co-expression network analysis (WGCNA) to identify shared genes, which were then subjected to further Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses. Furthermore, we employed a rigorous analytical approach by screening hub genes through both least absolute shrinkage and selection operator (LASSO) regression and support vector machine (SVM), and subsequently constructing a receiver operating characteristic (ROC) curve based on the screening outcomes. Finally, we utilized single-sample gene set enrichment analysis (ssGSEA) to comprehensively evaluate the levels of infiltration of 28 immune cells within the expression profile and their potential association with the shared hub genes. Results Using the WGCNA method, we identified 30 genes that appear to be involved in the pathological progression of both AF and CD. Through GO enrichment analysis on the key gene modules derived from WGCNA, we observed a significant enrichment of pathways related to major histocompatibility complex (MHC) and antigen processing. By leveraging the intersection of LASSO and SVM algorithms, we were able to pinpoint two overlapping genes, namely CXCL16 and HLA-DPB1. Additionally, we evaluated the infiltration of immune cells and observed the upregulation of CD4+ and CD8+ T cells, as well as dendritic cells in patients with AF and CD. Conclusions By employing bioinformatics tools, we conducted an investigation with the objective of elucidating the genetic foundations that connect AF and CD. This study culminated in the identification of CXCL16 and HLA-DPB1 as the most substantial genes implicated in the development of both disorders. Our findings suggest that the immune responses mediated by CD4+ and CD8+ T cells, along with dendritic cells, may hold a crucial role in the intricate interplay between AF and CD.
Collapse
Affiliation(s)
- Xiaohan Qiu
- National Key Laboratory for Innovation and Transformation of Luobing Theory, the Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences, Jinan, China
- Department of Cardiology, Qilu Hospital of Shandong University, Jinan, China
| | - Junlin Teng
- National Key Laboratory for Innovation and Transformation of Luobing Theory, the Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences, Jinan, China
- Department of Cardiology, Qilu Hospital of Shandong University, Jinan, China
| | - Ning Wang
- National Key Laboratory for Innovation and Transformation of Luobing Theory, the Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences, Jinan, China
- Department of Cardiology, Qilu Hospital of Shandong University, Jinan, China
| | - Luying Cao
- National Key Laboratory for Innovation and Transformation of Luobing Theory, the Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences, Jinan, China
- Department of Cardiology, Qilu Hospital of Shandong University, Jinan, China
| | - Congyi Cheng
- National Key Laboratory for Innovation and Transformation of Luobing Theory, the Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences, Jinan, China
- Department of Cardiology, Qilu Hospital of Shandong University, Jinan, China
| | - Cong Su
- National Key Laboratory for Innovation and Transformation of Luobing Theory, the Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences, Jinan, China
- Department of Cardiology, Qilu Hospital of Shandong University, Jinan, China
| | - Youran Dong
- National Key Laboratory for Innovation and Transformation of Luobing Theory, the Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences, Jinan, China
- Department of Cardiology, Qilu Hospital of Shandong University, Jinan, China
| | - Fen Wang
- National Key Laboratory for Innovation and Transformation of Luobing Theory, the Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences, Jinan, China
- Department of Cardiology, Qilu Hospital of Shandong University, Jinan, China
| | - Wenqiang Chen
- National Key Laboratory for Innovation and Transformation of Luobing Theory, the Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences, Jinan, China
- Department of Cardiology, Qilu Hospital of Shandong University, Jinan, China
| |
Collapse
|
18
|
Weber MC, Schmidt K, Buck A, Kasajima A, Becker S, Li C, Reischl S, Wilhelm D, Steiger K, Friess H, Neumann PA. Fractal analysis of extracellular matrix for observer-independent quantification of intestinal fibrosis in Crohn's disease. Sci Rep 2024; 14:3988. [PMID: 38368499 PMCID: PMC10874456 DOI: 10.1038/s41598-024-54545-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2023] [Accepted: 02/14/2024] [Indexed: 02/19/2024] Open
Abstract
Prevention of intestinal fibrosis remains an unresolved problem in the treatment of Crohn's disease (CD), as specific antifibrotic therapies are not yet available. Appropriate analysis of fibrosis severity is essential for assessing the therapeutic efficacy of potential antifibrotic drugs. The aim of this study was to develop an observer-independent method to quantify intestinal fibrosis in surgical specimens from patients with CD using structural analysis of the extracellular matrix (ECM). We performed fractal analysis in fibrotic and control histological sections of patients with surgery for CD (n = 28). To specifically assess the structure of the collagen matrix, polarized light microscopy was used. A score to quantify collagen fiber alignment and the color of the polarized light was established. Fractal dimension as a measure for the structural complexity correlated significantly with the histological fibrosis score whereas lacunarity as a measure for the compactness of the ECM showed a negative correlation. Polarized light microscopy to visualize the collagen network underlined the structural changes in the ECM network in advanced fibrosis. In conclusion, observer-independent quantification of the structural complexity of the ECM by fractal analysis is a suitable method to quantify the degree of intestinal fibrosis in histological samples from patients with CD.
Collapse
Affiliation(s)
- Marie-Christin Weber
- Department of Surgery, TUM School of Medicine and Health, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany
| | - Konstantin Schmidt
- Department of Surgery, TUM School of Medicine and Health, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany
| | - Annalisa Buck
- Department of Surgery, TUM School of Medicine and Health, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany
- Institute for Advanced Study, Technical University of Munich, Munich, Germany
| | - Atsuko Kasajima
- Institute of Pathology, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany
| | - Simon Becker
- Department of Mathematics, ETH Zurich, Zurich, Switzerland
| | - Chunqiao Li
- Department of Surgery, TUM School of Medicine and Health, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany
| | - Stefan Reischl
- Department of Surgery, TUM School of Medicine and Health, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany
- Institute of Diagnostic and Interventional Radiology, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany
| | - Dirk Wilhelm
- Department of Surgery, TUM School of Medicine and Health, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany
| | - Katja Steiger
- Institute of Pathology, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany
| | - Helmut Friess
- Department of Surgery, TUM School of Medicine and Health, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany
| | - Philipp-Alexander Neumann
- Department of Surgery, TUM School of Medicine and Health, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany.
- Institute for Advanced Study, Technical University of Munich, Munich, Germany.
| |
Collapse
|
19
|
Seco-Cervera M, Ortiz-Masiá D, Macias-Ceja DC, Coll S, Gisbert-Ferrándiz L, Cosín-Roger J, Bauset C, Ortega M, Heras-Morán B, Navarro-Vicente F, Millán M, Esplugues JV, Calatayud S, Barrachina MD. Resistance to apoptosis in complicated Crohn's disease: Relevance in ileal fibrosis. Biochim Biophys Acta Mol Basis Dis 2024; 1870:166966. [PMID: 37995775 DOI: 10.1016/j.bbadis.2023.166966] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2023] [Revised: 11/02/2023] [Accepted: 11/16/2023] [Indexed: 11/25/2023]
Abstract
BACKGROUND AND AIMS The stiffening of the extracellular matrix, and changes in its cellular and molecular composition, have been reported in the pathogenesis of fibrosis. We analyze the mechanisms that perpetuate ileal fibrosis in surgical resections of complicated Crohn's disease patients. METHODS Ileal resections were obtained from affected and non-affected tissue of stenotic or penetrating Crohn's disease behavior. Ilea from non-IBD patients were used as control tissue. All samples underwent RNA sequencing. Human small intestinal fibroblasts were treated for 48 h with IL-1β, TFGβ1, PDGFB or TNF-α. Resistance to apoptosis was analysed by RT-PCR, western blot and immunohistochemistry in ileal tissue and by RT-PCR and FACS in cultured cells. RESULTS Growth factor-driven signaling pathways and increased RAS GTPase activity were up-regulated in affected ilea in which we found expression of both the antiapoptotic molecule MCL1 and the transcription factor ETS1 in submucosal fibroblasts, and a senescence-associated secretory phenotype. In cultured intestinal fibroblasts, PDGFB induced an ETS1-mediated resistance to apoptosis that was associated with the induction of both of TGFB1 and IL1B, a cytokine that replicated the expression of SASP detected in ileal tissue. ETS1 drove fibroblast polarization between inflammatory and fibrogenic phenotypes in IL1β-treated cells. CONCLUSIONS Our data show resistance to apoptosis in complicated ileal CD, and demonstrate that PDGFB induce an ETS1-mediated resistance to apoptosis associated with an inflammatory and fibrogenic pattern of expression in intestinal fibroblasts. Results point to PDGFRB, IL1R1 or MCL1 as potential targets against ileal fibrosis.
Collapse
Affiliation(s)
- M Seco-Cervera
- Hospital Universitario Dr. Peset, FISABIO, Valencia, Spain.
| | - D Ortiz-Masiá
- Departamento de Medicina, Facultad de Medicina, Universidad de Valencia, Valencia, Spain; Hospital La Fe, Valencia, Spain.
| | - D C Macias-Ceja
- Departamento de Farmacología, Facultad de Medicina, Universidad de Valencia, Valencia, Spain.
| | - S Coll
- Departamento de Farmacología, Facultad de Medicina, Universidad de Valencia, Valencia, Spain.
| | - L Gisbert-Ferrándiz
- Departamento de Farmacología, Facultad de Medicina, Universidad de Valencia, Valencia, Spain.
| | - J Cosín-Roger
- Departamento de Farmacología, Facultad de Medicina, Universidad de Valencia, Valencia, Spain; CIBERehd, Valencia, Spain.
| | - C Bauset
- Departamento de Farmacología, Facultad de Medicina, Universidad de Valencia, Valencia, Spain.
| | - M Ortega
- Departamento de Anatomía Patológica, Facultad de Medicina, Universidad de Valencia, Valencia, Spain.
| | - B Heras-Morán
- Departamento de Anatomía Patológica, Facultad de Medicina, Universidad de Valencia, Valencia, Spain.
| | | | - M Millán
- Hospital La Fe, Valencia, Spain.
| | - J V Esplugues
- Departamento de Farmacología, Facultad de Medicina, Universidad de Valencia, Valencia, Spain; CIBERehd, Valencia, Spain.
| | - S Calatayud
- Departamento de Farmacología, Facultad de Medicina, Universidad de Valencia, Valencia, Spain; CIBERehd, Valencia, Spain.
| | - M D Barrachina
- Departamento de Farmacología, Facultad de Medicina, Universidad de Valencia, Valencia, Spain; CIBERehd, Valencia, Spain.
| |
Collapse
|
20
|
Yang W, Yu T, Cong Y. Stromal Cell Regulation of Intestinal Inflammatory Fibrosis. Cell Mol Gastroenterol Hepatol 2024; 17:703-711. [PMID: 38246590 PMCID: PMC10958116 DOI: 10.1016/j.jcmgh.2024.01.007] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/10/2023] [Revised: 01/09/2024] [Accepted: 01/09/2024] [Indexed: 01/23/2024]
Abstract
Intestinal inflammatory fibrosis is a severe consequence of inflammatory bowel diseases (IBDs). There is currently no cure for the treatment of intestinal fibrosis in IBD. Although inflammation is necessary for triggering fibrosis, the anti-inflammatory agents used to treat IBD are ineffective in preventing the progression of intestinal fibrosis and stricture formation once initiated, suggesting that inflammatory signals are not the sole drivers of fibrosis progression once it is established. Among multiple mechanisms involved in the initiation and progression of intestinal fibrosis in IBD, stromal cells play critical roles in mediating the process. In this review, we summarize recent progress on how stromal cells regulate intestinal fibrosis in IBD and how they are regulated by focusing on immune regulation and gut microbiota. We also outline the challenges moving forward in the field.
Collapse
Affiliation(s)
- Wenjing Yang
- Division of Gastroenterology and Hepatology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois; Center for Human Immunobiology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| | - Tianming Yu
- Division of Gastroenterology and Hepatology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois; Center for Human Immunobiology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| | - Yingzi Cong
- Division of Gastroenterology and Hepatology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois; Center for Human Immunobiology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
| |
Collapse
|
21
|
Cong J, Zhang H, Chen C. Definition and grading of anastomotic stricture/stenosis following low anastomosis after total mesorectal excision: A single-center study. Asian J Surg 2023; 46:3722-3726. [PMID: 36967350 DOI: 10.1016/j.asjsur.2023.03.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2022] [Revised: 01/31/2023] [Accepted: 03/08/2023] [Indexed: 06/18/2023] Open
Abstract
BACKGROUND Anastomotic stricture/stenosis (AS) is an alarming complication after colorectal surgery, and there is still no recognized definition for AS. This study aimed to determine the status and change of AS after rectal surgery using a special AS definition and grading system, discuss various risk factors for AS. METHODS This study included patients with rectal cancer who underwent total mesorectal excision between May 2014 and May 2021. A five-degree special AS definition and grading system was used to determine AS status, and clinical outcomes and risk factors for AS were investigated. RESULTS A total of 473 patients were enrolled in this study. Univariate and multivariate analyses of patient-related and technical risk factors for AS were performed 3 months postoperatively. For univariate analysis, female sex was a lower risk factor for AS. Defunctioning stoma, neoadjuvant chemoradiotherapy, chemotherapy, and anastomotic leakage were higher risk factors for AS (all p < 0.05). For multivariate analysis, only neoadjuvant chemoradiotherapy, chemotherapy, and anastomotic leakage were still higher risk factors for AS (all p < 0.05). CONCLUSIONS Through a special AS definition and grading system's evaluation, we noted that neoadjuvant chemoradiotherapy, chemotherapy, and anastomotic leakage were the higher risk factors for AS.
Collapse
Affiliation(s)
- Jinchun Cong
- Ward of Colorectal Tumor, Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
| | - Hong Zhang
- Ward of Colorectal Tumor, Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
| | - Chunsheng Chen
- Ward of Colorectal Tumor, Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
| |
Collapse
|
22
|
Tavares de Sousa H, Magro F. How to Evaluate Fibrosis in IBD? Diagnostics (Basel) 2023; 13:2188. [PMID: 37443582 DOI: 10.3390/diagnostics13132188] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2023] [Revised: 06/21/2023] [Accepted: 06/25/2023] [Indexed: 07/15/2023] Open
Abstract
In this review, we will describe the importance of fibrosis in inflammatory bowel disease (IBD) by discussing its distinct impact on Crohn's disease (CD) and ulcerative colitis (UC) through their translation to histopathology. We will address the existing knowledge on the correlation between inflammation and fibrosis and the still not fully explained inflammation-independent fibrogenesis. Finally, we will compile and discuss the recent advances in the noninvasive assessment of intestinal fibrosis, including imaging and biomarkers. Based on the available data, none of the available cross-sectional imaging (CSI) techniques has proved to be capable of measuring CD fibrosis accurately, with MRE showing the most promising performance along with elastography. Very recent research with radiomics showed encouraging results, but further validation with reliable radiomic biomarkers is warranted. Despite the interesting results with micro-RNAs, further advances on the topic of fibrosis biomarkers depend on the development of robust clinical trials based on solid and validated endpoints. We conclude that it seems very likely that radiomics and AI will participate in the future non-invasive fibrosis assessment by CSI techniques in IBD. However, as of today, surgical pathology remains the gold standard for the diagnosis and quantification of intestinal fibrosis in IBD.
Collapse
Affiliation(s)
- Helena Tavares de Sousa
- Gastroenterology Department, Algarve University Hospital Center, 8500-338 Portimão, Portugal
- ABC-Algarve Biomedical Center, University of Algarve, 8005-139 Faro, Portugal
| | - Fernando Magro
- Unit of Pharmacology and Therapeutics, Department of Biomedicine, Faculty of Medicine, University of Porto, 4200-450 Porto, Portugal
- Department of Gastroenterology, São João University Hospital Center, 4200-319 Porto, Portugal
- CINTESIS@RISE, Faculty of Medicine, University of Porto, 4200-450 Porto, Portugal
| |
Collapse
|
23
|
Solitano V, Dal Buono A, Gabbiadini R, Wozny M, Repici A, Spinelli A, Vetrano S, Armuzzi A. Fibro-Stenosing Crohn's Disease: What Is New and What Is Next? J Clin Med 2023; 12:jcm12093052. [PMID: 37176493 PMCID: PMC10179180 DOI: 10.3390/jcm12093052] [Citation(s) in RCA: 14] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2023] [Revised: 04/03/2023] [Accepted: 04/19/2023] [Indexed: 05/15/2023] Open
Abstract
Fibro-stenosing Crohn's disease (CD) is a common disease presentation that leads to impaired quality of life and often requires endoscopic treatments or surgery. From a pathobiology perspective, the conventional view that intestinal fibro-stenosis is an irreversible condition has been disproved. Currently, there are no existing imaging techniques that can accurately quantify the amount of fibrosis within a stricture, and managing patients is challenging, requiring a multidisciplinary team. Novel therapies targeting different molecular components of the fibrotic pathways are increasing regarding other diseases outside the gut. However, a large gap between clinical need and the lack of anti-fibrotic agents in CD remains. This paper reviews the current state of pathobiology behind fibro-stenosing CD, provides an updated diagnostic and therapeutic approach, and finally, focuses on clinical trial endpoints and possible targets of anti-fibrotic therapies.
Collapse
Affiliation(s)
- Virginia Solitano
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20090 Milan, Italy
- Division of Gastroenterology, Department of Medicine, Western University, London, ON N6A 4V2, Canada
| | - Arianna Dal Buono
- IBD Center, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy
| | - Roberto Gabbiadini
- IBD Center, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy
| | - Marek Wozny
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20090 Milan, Italy
| | - Alessandro Repici
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20090 Milan, Italy
- Department of Endoscopy, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy
| | - Antonino Spinelli
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20090 Milan, Italy
- Division of Colon and Rectal Surgery, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy
| | - Stefania Vetrano
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20090 Milan, Italy
- IBD Center, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy
| | - Alessandro Armuzzi
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20090 Milan, Italy
- IBD Center, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy
| |
Collapse
|
24
|
Steiner CA, Koch SD, Evanoff T, Welch N, Kostelecky R, Callahan R, Murphy EM, Hall CHT, Lu S, Weiser-Evans MC, Cartwright IM, Colgan SP. The TNF ΔARE mouse as a model of intestinal fibrosis. BIORXIV : THE PREPRINT SERVER FOR BIOLOGY 2023:2023.01.13.523973. [PMID: 36712048 PMCID: PMC9882211 DOI: 10.1101/2023.01.13.523973] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
Background & Aims Crohn's disease (CD) is a highly morbid chronic inflammatory disease. The majority of CD patients also develop fibrostenosing complications. Despite this, there are no medical therapies for intestinal fibrosis. This is in part due to lack of high-fidelity biomimetic models to enhance understanding and drug development. There is a need to develop in vivo models of inflammatory bowel disease-related intestinal fibrosis. We sought to determine if the TNF ΔARE mouse, a model of ileal inflammation, may also develop intestinal fibrosis. Methods Several clinically relevant outcomes were studied including features of structural fibrosis, histological fibrosis, and gene expression. These include the use of a luminal casting technique we developed, traditional histological outcomes, use of second harmonic imaging, and quantitative PCR. These features were studied in aged TNF ΔARE mice as well as in cohorts of numerous ages. Results At ages of 24+ weeks, TNF ΔARE mice develop structural, histological, and genetic changes of ileal fibrosis. Genetic expression profiles have changes as early as six weeks, followed by histological changes occurring as early as 14-15 weeks, and overt structural fibrosis delayed until after 24 weeks. Discussion The TNF ΔARE mouse is a viable and highly tractable model of intestinal fibrosis. This model and the techniques employed can be leveraged for both mechanistic studies and therapeutic development for the treatment of intestinal fibrosis.
Collapse
|
25
|
Meng J, Luo Z, Chen Z, Zhou J, Chen Z, Lu B, Zhang M, Wang Y, Yuan C, Shen X, Huang Q, Zhang Z, Ye Z, Cao Q, Zhou Z, Xu Y, Mao R, Chen M, Sun C, Li Z, Feng ST, Meng X, Huang B, Li X. Intestinal fibrosis classification in patients with Crohn's disease using CT enterography-based deep learning: comparisons with radiomics and radiologists. Eur Radiol 2022; 32:8692-8705. [PMID: 35616733 DOI: 10.1007/s00330-022-08842-z] [Citation(s) in RCA: 30] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2021] [Revised: 04/13/2022] [Accepted: 04/25/2022] [Indexed: 12/27/2022]
Abstract
OBJECTIVES Accurate evaluation of bowel fibrosis in patients with Crohn's disease (CD) remains challenging. Computed tomography enterography (CTE)-based radiomics enables the assessment of bowel fibrosis; however, it has some deficiencies. We aimed to develop and validate a CTE-based deep learning model (DLM) for characterizing bowel fibrosis more efficiently. METHODS We enrolled 312 bowel segments of 235 CD patients (median age, 33 years old) from three hospitals in this retrospective study. A training cohort and test cohort 1 were recruited from center 1, while test cohort 2 from centers 2 and 3. All patients performed CTE within 3 months before surgery. The histological fibrosis was semi-quantitatively assessed. A DLM was constructed in the training cohort based on a 3D deep convolutional neural network with 10-fold cross-validation, and external independent validation was conducted on the test cohorts. The radiomics model (RM) was developed with 4 selected radiomics features extracted from CTE images by using logistic regression. The evaluation of CTE images was performed by two radiologists. DeLong's test and a non-inferiority test were used to compare the models' performance. RESULTS DLM distinguished none-mild from moderate-severe bowel fibrosis with an area under the receiver operator characteristic curve (AUC) of 0.828 in the training cohort and 0.811, 0.808, and 0.839 in the total test cohort, test cohorts 1 and 2, respectively. In the total test cohort, DLM achieved better performance than two radiologists (*1 AUC = 0.579, *2 AUC = 0.646; both p < 0.05) and was not inferior to RM (AUC = 0.813, p < 0.05). The total processing time for DLM was much shorter than that of RM (p < 0.001). CONCLUSION DLM is better than radiologists in diagnosing intestinal fibrosis on CTE in patients with CD and not inferior to RM; furthermore, it is more time-saving compared to RM. KEY POINTS • Question Could computed tomography enterography (CTE)-based deep learning model (DLM) accurately distinguish intestinal fibrosis severity in patients with Crohn's disease (CD)? • Findings In this cross-sectional study that included 235 patients with CD, DLM achieved better performance than that of two radiologists' interpretation and was not inferior to RM with significant differences and much shorter processing time. • Meaning This DLM may accurately distinguish the degree of intestinal fibrosis in patients with CD and guide gastroenterologists to formulate individualized treatment strategies for those with bowel strictures.
Collapse
Affiliation(s)
- Jixin Meng
- Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, 58 Zhongshan II Road, Guangzhou, 510080, People's Republic of China
| | - Zixin Luo
- Medical AI Lab, School of Biomedical Engineering, Health Science Center, Shenzhen University, Block A2, Lihu Campus of Shenzhen University, 1066 Xueyuan Avenue, Shenzhen, 518000, People's Republic of China
| | - Zhihui Chen
- Department of Gastrointestinal and Pancreatic Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, People's Republic of China
| | - Jie Zhou
- Department of Radiology, The Sixth Affiliated Hospital, Sun Yat-sen University, Yuancun Er Heng Road, NO.26, Guangzhou, 510655, People's Republic of China
| | - Zhao Chen
- Department of Medical Imaging Center, Nan Fang Hospital, Southern Medical University, 1838 Guangzhou Avenue North, Guangzhou, 510515, People's Republic of China
| | - Baolan Lu
- Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, 58 Zhongshan II Road, Guangzhou, 510080, People's Republic of China
| | - Mengchen Zhang
- Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, 58 Zhongshan II Road, Guangzhou, 510080, People's Republic of China
| | - Yangdi Wang
- Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, 58 Zhongshan II Road, Guangzhou, 510080, People's Republic of China
| | - Chenglang Yuan
- Medical AI Lab, School of Biomedical Engineering, Health Science Center, Shenzhen University, Block A2, Lihu Campus of Shenzhen University, 1066 Xueyuan Avenue, Shenzhen, 518000, People's Republic of China
| | - Xiaodi Shen
- Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, 58 Zhongshan II Road, Guangzhou, 510080, People's Republic of China
| | - Qinqin Huang
- Medical AI Lab, School of Biomedical Engineering, Health Science Center, Shenzhen University, Block A2, Lihu Campus of Shenzhen University, 1066 Xueyuan Avenue, Shenzhen, 518000, People's Republic of China
| | - Zhuya Zhang
- Medical AI Lab, School of Biomedical Engineering, Health Science Center, Shenzhen University, Block A2, Lihu Campus of Shenzhen University, 1066 Xueyuan Avenue, Shenzhen, 518000, People's Republic of China
| | - Ziyin Ye
- Department of Pathology, The First Affiliated Hospital, Sun Yat-sen University, 58 Zhongshan II Road, Guangzhou, 510080, People's Republic of China
| | - Qinghua Cao
- Department of Pathology, The First Affiliated Hospital, Sun Yat-sen University, 58 Zhongshan II Road, Guangzhou, 510080, People's Republic of China
| | - Zhiyang Zhou
- Department of Radiology, The Sixth Affiliated Hospital, Sun Yat-sen University, Yuancun Er Heng Road, NO.26, Guangzhou, 510655, People's Republic of China
| | - Yikai Xu
- Department of Medical Imaging Center, Nan Fang Hospital, Southern Medical University, 1838 Guangzhou Avenue North, Guangzhou, 510515, People's Republic of China
| | - Ren Mao
- Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, 58 Zhongshan II Road, Guangzhou, 510080, People's Republic of China
- Department of Gastroenterology, Hepatology and Nutrition, Digestive Diseases and Surgery Institute, Cleveland Clinic, Cleveland, OH, USA
| | - Minhu Chen
- Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, 58 Zhongshan II Road, Guangzhou, 510080, People's Republic of China
| | - Canhui Sun
- Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, 58 Zhongshan II Road, Guangzhou, 510080, People's Republic of China
| | - Ziping Li
- Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, 58 Zhongshan II Road, Guangzhou, 510080, People's Republic of China
| | - Shi-Ting Feng
- Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, 58 Zhongshan II Road, Guangzhou, 510080, People's Republic of China
| | - Xiaochun Meng
- Department of Radiology, The Sixth Affiliated Hospital, Sun Yat-sen University, Yuancun Er Heng Road, NO.26, Guangzhou, 510655, People's Republic of China
| | - Bingsheng Huang
- Medical AI Lab, School of Biomedical Engineering, Health Science Center, Shenzhen University, Block A2, Lihu Campus of Shenzhen University, 1066 Xueyuan Avenue, Shenzhen, 518000, People's Republic of China.
| | - Xuehua Li
- Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, 58 Zhongshan II Road, Guangzhou, 510080, People's Republic of China.
| |
Collapse
|
26
|
Inflammatory bowel disease-specific findings are common morphological changes in the ileal pouch with ulcerative colitis. Sci Rep 2022; 12:20361. [PMID: 36437274 PMCID: PMC9701810 DOI: 10.1038/s41598-022-24708-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2022] [Accepted: 11/18/2022] [Indexed: 11/28/2022] Open
Abstract
Why inflammation is common in ileal pouches with ulcerative colitis (UC) is unclear. We therefore clarified the morphological changes in pouches and afferent limbs (AL) of patients with UC and explored the relationship between these findings. We evaluated the morphological findings (histological and endoscopic inflammation as the Pouchitis Disease Activity Index [PDAI] histology subscore [hPDAI] and endoscopy subscore [ePDAI], inflammatory bowel disease [IBD]-specific findings using the IBD score [SIBD], colonic metaplasia using the colonic metaplasia score [CMS], and goblet cell [GC] ratio) in the pouch and AL of patients with UC. A total of 261 pouchoscopies were analyzed. The pouch body had a higher hPDAI (p < 0.001), SIBD (p < 0.001), CMS (p < 0.001), GC ratio (p < 0.001), and ePDAI (p < 0.001) than the AL. The hPDAI was correlated with the SIBD (Spearman's coefficient r = 0.538; p < 0.001), CMS (r = 0.687; p < 0.001), and the ePDAI (r = 0.552; p < 0.001), but not with GC ratio (r = 0.175; p < 0.001) or the pouch usage duration (r = -0.057; p = 0.107). The incidence of histological inflammation was higher in specimens showing basal plasmacytosis with severe mononuclear cell infiltration (BP) than in those without BP (odds ratio [OR] 6.790, p < 0.001), BP was commonly found with crypt hyperplasia (OR 3.414, p < 0.001) and the crypt length correlated with neutrophil infiltration (r = 0.469; p < 0.001). Histological inflammation, colonic metaplasia, the GC ratio, endoscopic inflammation, and IBD-specific findings were commonly present in the pouch than in the AL. Histological inflammation occurs with IBD-specific findings and colonic metaplasia, and these signify endoscopic inflammation.
Collapse
|
27
|
Tavares de Sousa H, Carneiro F. Understanding progression of strictures in ileal Crohn's disease-The importance of setting methodological standards. United European Gastroenterol J 2022; 10:915-916. [PMID: 36251489 PMCID: PMC9731658 DOI: 10.1002/ueg2.12327] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
Affiliation(s)
- Helena Tavares de Sousa
- Gastroenterology DepartmentAlgarve University Hospital CenterPortimãoPortugal
- ABC—Algarve Biomedical CenterUniversity of AlgarveFaroPortugal
| | - Fátima Carneiro
- Department of PathologySão João University Hospital Center and Faculty of MedicineUniversity of PortoPortoPortugal
- Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup)PortoPortugal
- Institute of Investigation and Innovation in Health (i3S)University of PortoPortoPortugal
| |
Collapse
|
28
|
Comparison of Anastomotic Stricture/Stenosis After Transanal Total Mesorectal Excision for Rectal Cancer with Laparoscopic Total Mesorectal Excision. Indian J Surg 2022. [DOI: 10.1007/s12262-022-03565-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
29
|
Steiner CA, Cartwright IM, Taylor CT, Colgan SP. Hypoxia-inducible factor as a bridge between healthy barrier function, wound healing, and fibrosis. Am J Physiol Cell Physiol 2022; 323:C866-C878. [PMID: 35912990 PMCID: PMC9467472 DOI: 10.1152/ajpcell.00227.2022] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2022] [Revised: 07/07/2022] [Accepted: 07/23/2022] [Indexed: 11/22/2022]
Abstract
The healthy mammalian intestine is lined by a single layer of epithelial cells. These cells provide a selectively permeable barrier to luminal contents and normally do so in an efficient and effective manner. Barrier function in the healthy mucosa is provided via several mechanisms including epithelial junctional complexes, mucus production, as well as mucosal-derived antimicrobial proteins. As tissue metabolism is central to the maintenance of homeostasis in the mucosa, intestinal [Formula: see text] levels are uniquely low due to counter-current blood flow and the presence of the microbiota, resulting in the stabilization of the transcription factor hypoxia-inducible factor (HIF). Ongoing studies have revealed that HIF molds normal intestinal metabolism and is central to the coordination of barrier regulation during both homeostasis and active disease. During acute inflammation, HIF is central to controlling the rapid restitution of the epithelium consistent with normal wound healing responses. In contrast, HIF may also contribute to the fibrostenotic response associated with chronic, nonresolving inflammation. As such, HIF may function as a double-edged sword in the overall course of the inflammatory response. Here, we review recent literature on the contribution of HIF to mucosal barrier function, wound healing, and fibrosis.
Collapse
Affiliation(s)
- Calen A Steiner
- Division of Gastroenterology and Hepatology, University of Colorado Anschutz Medical Campus, Aurora, Colorado
- Department of Medicine and the Mucosal Inflammation Program, University of Colorado School of Medicine, Aurora, Colorado
| | - Ian M Cartwright
- Division of Gastroenterology and Hepatology, University of Colorado Anschutz Medical Campus, Aurora, Colorado
- Department of Medicine and the Mucosal Inflammation Program, University of Colorado School of Medicine, Aurora, Colorado
- Rocky Mountain Regional Veterans Affairs Medical Center, Aurora, Colorado
| | - Cormac T Taylor
- School of Medicine, Conway Institute and Systems Biology Ireland, University College Dublin, Dublin, Ireland
| | - Sean P Colgan
- Division of Gastroenterology and Hepatology, University of Colorado Anschutz Medical Campus, Aurora, Colorado
- Department of Medicine and the Mucosal Inflammation Program, University of Colorado School of Medicine, Aurora, Colorado
- Rocky Mountain Regional Veterans Affairs Medical Center, Aurora, Colorado
| |
Collapse
|
30
|
Fibromuscular Expansion in Crohn's Disease Ileal Strictures: An Open Issue. Clin Gastroenterol Hepatol 2022; 21:1378-1380. [PMID: 35850408 DOI: 10.1016/j.cgh.2022.06.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/23/2022] [Accepted: 06/25/2022] [Indexed: 02/07/2023]
|
31
|
Neufert C. Transmural intestinal fibrosis in men and mice. Gut 2022; 71:1242-1244. [PMID: 34725200 DOI: 10.1136/gutjnl-2021-325522] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/15/2021] [Accepted: 10/23/2021] [Indexed: 12/08/2022]
Affiliation(s)
- Clemens Neufert
- Department of Medicine 1, Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitätsklinikum Erlangen, Erlangen, Bavaria, Germany .,Deutsches Zentrum Immuntherapie (DZI), Erlangen, Bavaria, Germany
| |
Collapse
|
32
|
Lin X, Wang Y, Liu Z, Lin S, Tan J, He J, Hu F, Wu X, Ghosh S, Chen M, Liu F, Mao R. Intestinal strictures in Crohn's disease: a 2021 update. Therap Adv Gastroenterol 2022; 15:17562848221104951. [PMID: 35757383 PMCID: PMC9218441 DOI: 10.1177/17562848221104951] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/01/2022] [Accepted: 05/17/2022] [Indexed: 02/04/2023] Open
Abstract
Intestinal strictures remain one of the most intractable and common complications of Crohn's disease (CD). Approximately 70% of CD patients will develop fibrotic strictures after 10 years of CD diagnosis. Since specific antifibrotic therapies are unavailable, endoscopic balloon dilation and surgery remain the mainstay treatments despite a high recurrence rate. Besides, there are no reliable methods for accurately evaluating intestinal fibrosis. This is largely due to the fact that the mechanisms of initiation and propagation of intestinal fibrosis are poorly understood. There is growing evidence implying that the pathogenesis of stricturing CD involves the intricate interplay of factors including aberrant immune and nonimmune responses, host-microbiome dysbiosis, and genetic susceptibility. Currently, the progress on intestinal strictures has been fueled by the advent of novel techniques, such as single-cell sequencing, multi-omics, and artificial intelligence. Here, we perform a timely and comprehensive review of the substantial advances in intestinal strictures in 2021, aiming to provide prompt information regarding fibrosis and set the stage for the improvement of diagnosis, treatment, and prognosis of intestinal strictures.
Collapse
Affiliation(s)
- Xiaoxuan Lin
- Department of Gastroenterology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
| | - Yu Wang
- Department of Gastroenterology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
| | - Zishan Liu
- Department of Gastroenterology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
| | - Sinan Lin
- Department of Gastroenterology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
| | - Jinyu Tan
- Department of Gastroenterology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
| | - Jinshen He
- Department of Gastroenterology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
| | - Fan Hu
- Department of Gastroenterology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
| | - Xiaomin Wu
- Department of Gastroenterology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
| | - Subrata Ghosh
- APC Microbiome Ireland, University College Cork, Cork, Ireland
| | - Minhu Chen
- Department of Gastroenterology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
| | - Fen Liu
- Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, 58 Zhongshan Road 2nd, Guangzhou 510080, People’s Republic of China
| | - Ren Mao
- Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, 58 Zhongshan Road 2nd, Guangzhou 510080, People’s Republic of China
- Department of Gastroenterology, Huidong People’s Hospital, Huizhou 516399, China
| |
Collapse
|
33
|
Biomechanical Properties of Strictures in Crohn’s Disease: Can Dynamic Contrast-Enhanced Ultrasonography and Magnetic Resonance Enterography Predict Stiffness? Diagnostics (Basel) 2022; 12:diagnostics12061370. [PMID: 35741180 PMCID: PMC9221822 DOI: 10.3390/diagnostics12061370] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2022] [Revised: 05/24/2022] [Accepted: 05/31/2022] [Indexed: 11/17/2022] Open
Abstract
Strictures and abdominal pain often complicate Crohn’s disease (CD). The primary aim was to explore whether parameters obtained by preoperative contrast-enhanced (CE) ultrasonography (US) and dynamic CE MR Enterography (DCE-MRE) of strictures associates with biomechanical properties. CD patients undergoing elective small intestinal surgery were preoperatively examined with DCE-MRE and CEUS. The excised intestine was distended utilizing a pressure bag. Luminal and outer bowel wall cross-sectional areas were measured with US. The circumferential stricture stiffness (Young’s modulus E) was computed. Stiffness was associated with the initial slope of enhancement on DCE-MRE (ρ = 0.63, p = 0.007), reflecting active disease, but lacked association with CEUS parameters. For structural imaging parameters, inflammation and stricture stiffness were associated with prestenotic dilatation on US (τb = 0.43, p = 0.02) but not with MRE (τb = 0.01, p = 1.0). Strictures identified by US were stiffer, 16.8 (14.0–20.1) kPa, than those graded as no or uncertain strictures, 12.6 (10.5–15.1) kPa, p = 0.02. MRE global score (activity) was associated with E (ρ = 0.55, p = 0.018). Elastography did not correlate with circumferential stiffness. We conclude that increasing activity defined by the initial slope of enhancement on DCE-MRE and MRE global score were associated with stricture stiffness. Prestenotic dilatation on US could be a potential biomarker of CD small intestinal stricture stiffness.
Collapse
|
34
|
Loch FN, Kamphues C, Beyer K, Klauschen F, Schineis C, Weixler B, Lauscher JC, Dorenbeck M, Bayerl C, Reiter R. Diagnostic Accuracy of Magnetic Resonance Enterography for the Evaluation of Active and Fibrotic Inflammation in Crohn’s Disease. Front Surg 2022; 9:872596. [PMID: 35647009 PMCID: PMC9136038 DOI: 10.3389/fsurg.2022.872596] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2022] [Accepted: 04/21/2022] [Indexed: 01/01/2023] Open
Abstract
Background Despite the success of standard magnetic resonance enterography (MRE) in detecting Crohn’s disease (CD), characterization of strictures and, thus, therapy guidance is still limited. The aim of the study was to determine diagnostic accuracy of MRE in detecting or ruling out active inflammation and identifying fibrotic lesions in patients with terminal ileal CD with histopathology as reference. Methods Sixty-seven consecutive patients (median age 32 years, range 19–79 years) with terminal ileal CD were retrospectively enrolled between January 2015 and October 2020. The median interval between MRE and surgery was 9 days (range 0–86 days). Sensitivity, specificity, positive and negative predictive value (PPV and NPV, respectively), and area under the curve (AUC) with 95% confidence intervals (CIs) were calculated for the MRE-based AIS (acute inflammation score) using the histopathology of surgical specimens as the reference standard. Results Sensitivity, specificity, PPV, and NPV for detecting or ruling out active inflammation were 100% (CI, 0.94–1.00; 0.44–1.00; 0.93–1.00; 0.31–1.00) using an AIS cut-off of >4.1. AUC was 1.00 (CI, 1.00–1.00; p < 0.01). In all patients with fibrotic changes only and no active inflammation, AIS was <4.1. Interobserver agreement was substantial (κ = 0.65, p < 0.01). Conclusion Our study has shown an excellent diagnostic performance of the MRE-based AIS for determining whether active inflammation is present or lesions are due to chronic changes in ileal CD using the histopathology of surgical specimens as reference. These findings indicate that the MRE-based AIS allows a better determination of the inflammatory stage of terminal ileal CD, which facilitates the decision to perform surgery.
Collapse
Affiliation(s)
- Florian N. Loch
- Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt–Universität zu Berlin, Department of Surgery, Berlin, Germany
- Correspondence: Florian N. Loch
| | - Carsten Kamphues
- Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt–Universität zu Berlin, Department of Surgery, Berlin, Germany
| | - Katharina Beyer
- Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt–Universität zu Berlin, Department of Surgery, Berlin, Germany
| | - Frederick Klauschen
- Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt–Universität zu Berlin, Insitute for Pathology, Berlin, Germany
| | - Christian Schineis
- Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt–Universität zu Berlin, Department of Surgery, Berlin, Germany
| | - Benjamin Weixler
- Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt–Universität zu Berlin, Department of Surgery, Berlin, Germany
| | - Johannes C. Lauscher
- Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt–Universität zu Berlin, Department of Surgery, Berlin, Germany
| | - Marc Dorenbeck
- Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt–Universität zu Berlin, Department of Surgery, Berlin, Germany
| | - Christian Bayerl
- Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt–Universität zu Berlin, Department of Radiology, Berlin, Germany
| | - Rolf Reiter
- Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt–Universität zu Berlin, Department of Radiology, Berlin, Germany
- Berlin Institute of Health at Charité – Universitätsmedizin Berlin, Berlin, Germany
| |
Collapse
|
35
|
Comparison of fecal calprotectin and pancreatic elastase assays based on proficiency testing results. Clin Biochem 2022; 107:19-23. [DOI: 10.1016/j.clinbiochem.2022.05.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2022] [Revised: 04/26/2022] [Accepted: 05/11/2022] [Indexed: 12/14/2022]
|
36
|
Wilkens R, Dolinger M, Burisch J, Maaser C. Point-of-Care Testing and Home Testing: Pragmatic Considerations for Widespread Incorporation of Stool Tests, Serum Tests, and Intestinal Ultrasound. Gastroenterology 2022; 162:1476-1492. [PMID: 34995530 DOI: 10.1053/j.gastro.2021.10.052] [Citation(s) in RCA: 25] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/30/2021] [Revised: 10/13/2021] [Accepted: 10/28/2021] [Indexed: 12/12/2022]
Abstract
Breaking through the biologic therapy efficacy plateau for inflammatory bowel disease requires the strategic development of personalized biomarkers in the tight control model. After risk stratification early in the disease course, targeted serial monitoring consistently to assess clinical outcomes in response to therapy allows for quick therapeutic adjustments before bowel damage can occur. Point-of-care intestinal ultrasound performed by the treating gastroenterologist is an accurate cross- sectional biomarker that monitors intestinal inflammation in real-time, enhances patient care, and increases shared understanding to help achieve common treatment goals. Combining intestinal ultrasound during a clinic visit with existing serum and stool biomarkers in a home testing setup with electronic health monitoring allows for an optimized, patient-centered personalized treatment algorithm that may improve treatment outcomes. Here, we review the current state, pragmatic considerations, and future implications of point-of-care testing and home testing for noninvasive inflammatory bowel disease monitoring in the tight control model.
Collapse
Affiliation(s)
- Rune Wilkens
- Gastrounit, Division of Medicine, Copenhagen University Hospital Hvidovre, Hvidovre, Copenhagen, Denmark; Copenhagen Center for Inflammatory Bowel Disease in Children, Adolescents and Adults, University of Copenhagen, Hvidovre Hospital, Denmark; Digestive Disease Center, Copenhagen University Hospital - Bispebjerg & Frederiksberg, Copenhagen, Denmark.
| | - Michael Dolinger
- Susan and Leonard Feinstein Inflammatory Bowel Disease Center, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Johan Burisch
- Gastrounit, Division of Medicine, Copenhagen University Hospital Hvidovre, Hvidovre, Copenhagen, Denmark; Copenhagen Center for Inflammatory Bowel Disease in Children, Adolescents and Adults, University of Copenhagen, Hvidovre Hospital, Denmark
| | - Christian Maaser
- Inflammatory Bowel Disease Outpatient Unit, Department of Geriatric Medicine, University Teaching Hospital Lueneburg, Lueneburg, Germany
| |
Collapse
|
37
|
Goren I, Rieder F. Endoscopic interventions for stricturing Crohn's disease. Lancet Gastroenterol Hepatol 2022; 7:279-280. [DOI: 10.1016/s2468-1253(21)00429-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2021] [Accepted: 11/04/2021] [Indexed: 10/19/2022]
|
38
|
Extracellular Matrix Components as Diagnostic Tools in Inflammatory Bowel Disease. BIOLOGY 2021; 10:biology10101024. [PMID: 34681123 PMCID: PMC8533508 DOI: 10.3390/biology10101024] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/18/2021] [Revised: 09/14/2021] [Accepted: 09/30/2021] [Indexed: 12/20/2022]
Abstract
Simple Summary For decades, the extracellular matrix (ECM) has been defined as a structure component playing a rather neglected role in the human body. In recent years, research has shed light on the role of ECM within cellular processes, including proliferation, migration and differentiation, as well as in inflammation. In inflammation, ECM composition is constantly being remodeled and undergoes dynamic and rapid changes. Tracking these changes could serve as a novel diagnostic tool. Inflammatory bowel disease is accompanied by complications such as fibrosis, stenosis and fistulas. All of these structural complications involve excessive synthesis or degradation of ECM. With this review, we explored whether the analysis of ECM composition can be of support in diagnosing inflammatory bowel disease and whether changes within ECM can help to predict a complicated disease course early on. Abstract Work from the last years indicates that the extracellular matrix (ECM) plays a direct role in various cellular processes, including proliferation, migration and differentiation. Besides homeostatic processes, its regulatory function in inflammation becomes more and more evident. In inflammation, such as inflammatory bowel disease, the ECM composition is constantly remodeled, and this can result in a structuring of fistulizing disease course. Thus, tracking early ECM changes might bear the potential to predict the disease course. In this review, we provide an overview of relevant diagnostic methods, focusing on ECM changes.
Collapse
|
39
|
Zhao J, Liao D, Wilkens R, Krogh K, Glerup H, Gregersen H. Bowel stiffness associated with histopathologic scoring of stenosis in patients with Crohn's disease. Acta Biomater 2021; 130:332-342. [PMID: 34119715 DOI: 10.1016/j.actbio.2021.06.011] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2021] [Revised: 05/31/2021] [Accepted: 06/03/2021] [Indexed: 12/11/2022]
Abstract
BACKGROUND AND AIMS Intestinal stenosis is a common complication of Crohn's Disease (CD). Stenosis is associated with alteration of bowel mechanical properties. This study aims to quantitate the mechanical properties of the intestinal stenosis and to explore associations between histology and mechanical remodeling at stenotic intestinal sites in CD patients. METHODS Intestinal segments from stenotic sites were studied in vitro from 19 CD patients. A luminal catheter with a bag was used to stepwise pressurize the intestinal segments from 0-100 cmH2O with 10 cmH2O increments. B-mode ultrasound images were obtained at the narrowest part of the stenosis at each pressure level and morphometric parameters were obtained from ultrasound images. The mechanical behavior of the stenotic tissue were characterized by using an isotropic three dimensional strain energy function in Demiray model form, the mechanical constants were obtained by fitting the model to the recorded intraluminal pressure and the inner radius of the stenotic segment of the small bowel. Grading scores were used for histological analysis of inflammation, fibrosis, muscular hypertrophy and adipocyte proliferation in the intestinal layers. The collagen area fraction in intestinal layers was also calculated. Associations between histological and the mechanical constants (stiffness) were analyzed. RESULTS Chronic inflammation was mainly located in mucosa whereas fibrosis was found in submucosa. The mechanical remodeling was performed with changed mechanical constants ranged between 0.35-13.68kPa. The mechanical properties changes were associated mainly with chronic inflammation, fibrosis and combination of inflammation and fibrosis (R>0.69, P<0.001). Furthermore, the mechanical properties correlated with the collagen fraction in submucosa and muscular layers (R>0.53, P<0.05). CONCLUSIONS We quantitated the intestinal stenosis stiffness. Associations were found between bowel mechanical remodeling and histological changes at the stenotic site in CD patients. STATEMENT OF SIGNIFICANCE Although intestinal ultrasonography, CT and MRI can be used to diagnose Crohn's Disease (CD)-associated bowel strictures, these techniques may not have sufficient accuracy and resolution to differentiate predominantly inflammatory strictures from predominantly fibrotic strictures. The present study aims to quantitate the mechanical remodeling of intestinal stenosis and to explore the associations between histological parameters and mechanical properties at the intestinal stenotic sites in CD patients. For the first time, we quantitatively demonstrated that the mechanical properties of the intestinal wall in CD stenosis are associated with the chronic inflammation, fibrosis and collagen fraction in the intestinal layers. The results of this study may facilitate design and development of artificial biomaterials for gastrointestinal organs. The potential clinical implication of this study is that the histological characteristics in patients with CD can be predicted clinically by means of inflammation and fibrosis assessment in conjunction with tissue stiffness measurement.
Collapse
Affiliation(s)
- Jingbo Zhao
- Standard (Chongqing) Pathological Diagnosis Center. No. 8 Xiyuan North Road, Shapingba District, Chongqing, China; Mech-Sense, Department of Gastroenterology and Hepatology, Aalborg University Hospital, Denmark; Giome Academia, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
| | - Donghua Liao
- Mech-Sense, Department of Gastroenterology and Hepatology, Aalborg University Hospital, Denmark; Giome Academia, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
| | - Rune Wilkens
- Gastrounit, Division of Medicine, Hvidovre Hospital, University of Copenhagen, Copenhagen, Denmark; Diagnostic Centre, University Research Clinic for Innovative Patient Pathways, Silkeborg Regional Hospital, Silkeborg, Denmark
| | - Klaus Krogh
- Neurogastroenterology Unit, Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark
| | - Henning Glerup
- Diagnostic Centre, University Research Clinic for Innovative Patient Pathways, Silkeborg Regional Hospital, Silkeborg, Denmark
| | | |
Collapse
|